

Name	<b>Daniele SANTINI; MD, PhD</b>
Birth Place and Date	Merano (BZ), Italy; August 28, 1964
Fiscal Code-Nationality	SNTDNL64M28F132O - Italy
Languages	Italian, English (British Academy, VI level)
Permanent Address	00188 Rome, Italy, Via della Giustiniana 401
Present Occupation	Full Professor in Medical Oncology Campus Bio-Medico University of Rome
Phone-Fax	
Mobile	
<b>E-mail</b>	<b><u><a href="mailto:d.santini@unicampus.it">d.santini@unicampus.it</a></u></b>

### **A. Education and training**

<b>2001</b>	PhD in Immunopharmacology, University of Palermo
<b>1994</b>	Resident-Specialty in Medical Oncology (score 70/70), University "La Sapienza" of Rome
<b>1990</b>	M.D. graduated cum laude, University "La Sapienza" of Rome

### **B. Professional and Academic Appointments**

<b>2018 – Today</b>	President of Medicine and Surgery Degree Course Campus Bio-Medico University of Rome
<b>2018 – Today</b>	Adjunct Full Professor in Molecular Biology, Temple University's College of Science and Technology, Philadelphia (USA)
<b>2017 - Today</b>	Full Professor in Medical Oncology Campus Bio-Medico University of Rome
<b>2016 - Today</b>	Study Coordinator of Medicine and Surgery Degree Course Campus Bio-Medico University of Rome
<b>2015 – 2018</b>	Adjunct Professor in Biology, Temple University's College of Science and Technology, Philadelphia (USA)
<b>2015- Today</b>	Coordinator of the Bachelor's Degree Medicine and Surgery Department of Medicine - Campus Bio-Medico University of Rome
<b>2013 – Today</b>	Member of Scientific Board of PhD Program: "Biomedical Sciences and Bio- Ethics, Campus Bio-Medico University of Rome
<b>2011 - Today</b>	Vice-director of Specialization School in Medical Oncology Campus Bio-Medico University of Rome
<b>2009 - Today</b>	Chief of Medical Oncology Day Hospital Campus Bio-Medico University-Hospital of Rome
<b>2007 – Today</b>	Co-chair of Oncology Research Unit

Campus Bio-Medico University of Rome

- 2010 - 2016** Associate Professor in General Pathology  
Campus Bio-Medico University of Rome
- 2007 - 2012** Member of Scientific Board of PhD Program: "Osteoncological  
Physiopathology", Campus Bio-Medico University of Rome
- 2001 - 2010** Researcher in Medical Oncology  
Campus Bio-Medico University of Rome
- 2006 - 2009** In charge of high specialization professional activities,  
Department of Medical Oncology, Campus Bio-Medico University of Rome

### **C. Teaching Activities ongoing at Campus Bio-Medico University of Rome**

Teacher of Immunology  
Medicine and Surgery Course

Teacher of Medical Oncology and palliative care  
Medicine and Surgery Course

Teacher of Medical Oncology  
Radiological Technical Course

Didactic and tutorial activities in Oncology  
Nursing course

Teacher in Palliative care  
Nursing Course

Teacher of Cellular and Humoral Immunity  
Hematology Specialization School

Teacher of Osteoncological Pathology and Methodology of Oncological  
Research  
Oncology Specialization School

Teacher of Immunology  
Clinical Pathology Specialization,  
Microbiology and Virology Specialization School,  
Allergology Specialization School

Teacher of General Pathology  
Radiotherapy Specialization School

Teacher of Principles of General Pathology in Oncology  
General Surgery Specialization School

Teacher of Integrated therapies in Oncology  
Digestive System Surgery Specialization School

### **D. Awards, Research Competitive Calls**

- 09/14/2018** Special Award for Professional Career received by Italian Chamber of  
Deputies

- 2016** Co-winner research application “Bando Interno per progetti di ricerca utili a favorire la formazione di profili interdisciplinari in collaborazione tra l’Istituto FAST e le unità di ricerca dell’Ateneo sul tema dell’embodiment”, Campus Bio-Medico University of Rome, Project Title: “SELF-ON-A-CHIP”
- 2014-2015** Winner of the Bilateral project Italia-USA MAE  
Project Title: “Understanding the interplay between cancer stem cells and immune system: an innovative cells-on-chip approach”.
- 2013** Winner of Competition “Fondazione G. Berlucci for Cancer Research 2013”  
Project Title: “Cell-on-chip models for the development of integrated therapies of immunotherapy with the aim to overcome the resistance to conventional treatments in non small cell lung cancer: the role of interaction between cancer stem cells and macrophage polarization”.
- 2013** Co-winner research application PRIN 2012  
Project Title: “Cells-on-chip technologies for the study of endocannabinoid system in an in vivo model of cancer/immunity system interactions”.
- 2005** Scientific Director of the PRIN Research Unit PRIN 2005.  
Project Title: Modulation of Human Gamma/Delta T Lymphocytes and analysis of different biological parameters (Inflammatory cytokines, cytokines related to the immune response, pro-angiogenic factors, bone resorption markers) after zoledronic acid administration in patients with solid tumors.

#### **E. Cordinator, partecipation in the writing of national and international oncology guidelines**

- 2020** ESMO Clinical Practice Guidelines subject editor for the palliative care section
- 2018** Member of the “Genitourinary Faculty (GU)” for the European Society of Medical Oncology (ESMO)
- 2018** Coordinator of Guidelines on “Orphan symptoms” for the European Society of Medical Oncology (ESMO)
- 2018** Co-author of Guidelines “Skin toxicity” for the European Society of Medical Oncology (ESMO)
- 2018** Co-author of Guidelines “Bone Health” for the European Society of Medical Oncology (ESMO)
- 2012** Co-author of Management of cancer pain: ESMO Clinical Practice Guidelines 2012
- 2010-today** Coordinator of the National Guidelines on “Lung Bone metastases treatment” for the Italian Association of Toracic Oncology (AIOT)
- 2010-today** Co-author of the National Guidelines on “Prostate bone metastases treatment” for the Italian Society of Urology (SIU)
- 2008-today** Coordinator of the National Guidelines on “Bone metastases treatment” for the Italian Association of Medical Oncology (AIOM)
- 2011-2016** President of Italian Society of Osteoncology

## **F. Editorial Activity**

**2014-today**      **Accademic Editor** of PLOS ONE

**2013-today**      **Editor in chief** of Expert Opinion on Therapeutic Targets

**Member of the Editorial Board** of the International Scientific Journals:

Expert Opinion on Biological Therapy  
Expert Opinion on Emerging Drugs  
Critical Review in Oncology and Haematology  
Clinical medicine insights: oncology  
Journal of Chemotherapy

## **G. Scientific Societies' membership, advisor, President and affiliations**

**2014-today**              National Advisor, South Italy Oncology Group (GOIM)

**2014-today**              National Advisor, North West Oncology Group (GONO)

**2015-2017**              National President of Italian Society of Osteoncology (ISO)

**2011-2016**              Regional Advisor, Italian Association of Medical Oncology (AIOM)

## **H. Publications**

**524 publications on International peer reviewed journals with Impact Factor**

**Scopus Citations: 14040**

**Google Scholar citations 21592**

**H-Index Scopus: 54**

**H-Index Google Scholar: 68**

**Top Italian Scientists:**

**<http://www.topitalianscientists.org/top-italian-scientists/Daniele%20Santini>**

## List of publications

1. Dell'Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, Russano M, Cursano MC, Napolitano A, Zeppola T, Vincenzi B, Tonini G, Santini D. Prognostic and predictive factors in pancreatic cancer. *Oncotarget*. 2020 Mar 10;11(10):924-941. doi: 10.18632/oncotarget.27518.
2. Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorito G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol*. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9.
3. Russano M, Citarella F, Vincenzi B, Tonini G, Santini D. Coronavirus Disease 2019 or Lung Cancer: What Should We Treat? *J Thorac Oncol*. 2020 Apr 10:S1556-0864(20)30294-X. doi: 10.1016/j.jtho.2020.04.001.
4. Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. *Int J Cancer*. 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583.
5. Santini D, Berruti A, Di Maio M, Procopio G, Bracarda S, Ibrahim T, Bertoldo F. Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. *ESMO Open*. 2020 Mar;5(2):e000652. doi: 10.1136/esmoopen-2019-000652.
6. Pantano F, Russano M, Berruti A, Mansueto G, Migliorino MR, Adamo V, Aprile G, Gelibter A, Ficorella C, Falcone A, Russo A, Aieta M, Maio M, Martelli O, Barni S, Napolitano A, Roca E, Quadrini S, Iacono D, Russo A, Calvetti L, Occhipinti MA, Cortellini A, Vasile E, Passiglia F, Imperatori M, Calabrò L, Di Giacomo AM, Petrelli F, Pasquini G, Franchina T, Venditti O, Intagliata S, Galvano A, Fioroni I, Vincenzi B, Tonini G, Santini D. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. *Expert Opin Biol Ther*. 2020 Mar;20(3):319-326. doi:10.1080/14712598.2020.1724953.
7. Fusco V, Santini D, Campisi G, Bertoldo F, Lanzetta G, Ibrahim T, Bertetto O, Numico G, Addeo A, Berruti A, Bettini G, Saia G, Bedogni A. Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. *JCO Oncol Pract*. 2020 Mar;16(3):142-145. doi:10.1200/JOP.19.00645.
8. Salati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K, Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P, Cagnazzo C, Depetris I, Gelsomino F, Spallanzani A, Santini D, Silvestris N, Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini A. The prognostic nutritional index predicts survival and

- response to first-line chemotherapy in advanced biliary cancer. *Liver Int.* 2020 Mar;40(3):704-711. doi: 10.1111/liv.14314.
9. Stellato M, Cursano MC, Citarella F, Pantano F, Russano M, Dell' Aquila E, Vincenzi B, Tonini G, Santini D. Response to cabozantinib in renal cell carcinoma with cardiac metastases. *Anticancer Drugs.* 2020 Mar;31(3):314-318. doi: 10.1097/CAD.0000000000000889.
  10. Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, Kayal R, Sanguineti G, Marchetti P, Botticelli A, Marinelli D, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Tonini G, Santini D, Michelotti A, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Cazzaniga M, Moscetti L, Fabbri A, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Garufi C, Di Stefano P, Mirabelli R, Veltri E, Paris I, Giotta F, Lorusso V, Landucci E, Ficorella C, Roselli M, Adamo V, Ricciardi G, Russo A, Valerio MR, Berardi R, Pistelli M, Cannita K, Zamagni C, Garrone O, Baldini E, Livi L, Meattini I, Del Medico P, Generali D, De Maria R, Risi E, Ciliberto G, Villa A, Sperduti I, Mazzotta M, Barba M, Giordano A, Vici P. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. *J Cell Physiol.* 2020 Jan 15. doi: 10.1002/jcp.29445.
  11. Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni S, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadri S, Roca E, Vasile E, Imperatori M, Occhipinti M, Galvano A, Petrelli F, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR, Tonini G, Santini D, Adamo V. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. *Adv Ther.* 2020 Mar;37(3):1145-1155. doi: 10.1007/s12325-020-01229-w.
  12. Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. *Eur J Cancer.* 2020 Feb 4;128:17-26. doi: 10.1016/j.ejca.2019.12.031.
  13. Citarella F, Russano M, Pantano F, Dell'Aquila E, Vincenzi B, Tonini G, Santini D. Facing SARS-CoV-2 outbreak in immunotherapy era. *Future Oncol.* 2020 May 29;10.2217/fon-2020-0340. doi: 10.2217/fon-2020-0340.
  14. Santini D, Tonini G. Brief letter of a doctor to his psychologist in the COVID-19 outbreak era. *ESMO Open.* 2020 May;5(3):e000801. doi: 10.1136/esmoopen-2020-000801.
  15. Napolitano A, Provenzano S, Colombo C, Vitellaro M, Brunello A, Badalamenti G, Nannini M, Ibrahim T, Hohenberger P, Gasperoni S, Gennatas S, Jones RL, Hindi N, Martin-Broto J, Spalato Ceruso M, Silletta M, Dei Tos AP, Gronchi A, Stacchiotti S, Santini D, Tonini G, Palassini E, Vincenzi B. Familial adenomatous polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. *ESMO Open.* 2020 Jan;5(1):e000604. doi: 10.1136/esmoopen-2019-000604.
  16. Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, Pantano F, Dell'Aquila E, Anesi C, Silvestris N, Argentiero A, Solimando A, Vincenzi B, Tonini G, Santini D. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. *J Exp Clin Cancer Res.* 2020 May 27;39(1):95. doi: 10.1186/s13046-020-01601-2.
  17. Catalano V, Bergamo F, Cremolini C, Vincenzi B, Negri F, Giordani P, Alessandrini P, Intini R, Stragliotto S, Rossini D, Borelli B, Santini D, Sarti D, Rocchi MBL, Lonardi S, Falcone A, Zagonel V, Mattioli R, Graziano F. Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter,

- retrospective analysis on 685 patients. *J Cancer Res Clin Oncol*. 2020 Feb;146(2):493-501. doi: 10.1007/s00432-019-03077-w.
18. Silipigni S, Ippolito E, Matteucci P, Santo B, Gangemi E, La Cesa A, Santini D, Greco C, Ramella S. Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report. *Breast J*. 2020 Apr 11. doi: 10.1111/tbj.13844.
  19. Pantano F, Rossi E, Iuliani M, Facchinetti A, Simonetti S, Ribelli G, Zoccoli A, Vincenzi B, Tonini G, Zamarchi R, Santini D. Dynamic changes of Receptor activator of nuclear factor- $\kappa$ B expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. *Sci Rep*. 2020 Jan 28;10(1):1288. doi: 10.1038/s41598-020-58339-2
  20. Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fagnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C. Evaluating the role of FAMilly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. *Oncoimmunology*. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389.
  21. Rossini D, Germani MM, Pagani F, Pellino A, Dell'Aquila E, Bensi M, Liscia N, Moretto R, Boccaccino A, Prisciandaro M, Manglaviti S, Schirripa M, Vivolo R, Scartozzi M, Santini D, Salvatore L, Pietrantonio F, Loupakis F, Falcone A, Cremolini C. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. *Clin Colorectal Cancer*. 2020 Apr 11:S1533-0028(20)30046-3. doi: 10.1016/j.clcc.2020.03.009.
  22. Ruzzo A, Graziano F, Bagaloni I, Di Bartolomeo M, Prisciandaro M, Aprile G, Ongaro E, Vincenzi B, Perrone G, Santini D, Fornaro L, Vivaldi C, Tomasello G, Loupakis F, Lonardi S, Fassan M, Valmasoni M, Sarti D, Lorenzini P, Catalano V, Bisonni R, Del Prete M, Collina G, Magnani M. Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. *Gastric Cancer*. 2020 May 5. doi:10.1007/s10120-020-01078-0.
  23. Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fagnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. *Eur J Cancer*. 2020 May 23;134:19-28. doi: 10.1016/j.ejca.2020.04.025.
  24. Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari MA, Salvatore L, Tortora G, Rossini D, Germani MM, Boccaccino A, Dell'Aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino PD, Lombardi P, Keränen SR, Álvaro MH, Zurlo IV, Corsi DC, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti MA, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache SD, Porzio G, Ficorella C. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. *Cancers (Basel)*. 2020 May 16;12(5):E1259. doi: 10.3390/cancers12051259.
  25. Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F,

- Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of  $\geq 50$ . *Cancer Immunol Immunother*. 2020 May 30. doi: 10.1007/s00262-020-02613-9.
26. Fusco V, Santini D, Campisi G, Bertoldo F, Lanzetta G, Ibrahim T, Bertetto O, Numico G, Addeo A, Berruti A, Bettini G, Saia G, Bedogni A. Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. *JCO Oncol Pract*. 2020 Mar;16(3):142-145. doi:10.1200/JOP.19.00645.
  27. Salati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K, Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P, Cagnazzo C, Depetris I, Gelsomino F, Spallanzani A, Santini D, Silvestris N, Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini A. The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. *Liver Int*. 2020 Mar;40(3):704-711. doi: 10.1111/liv.14314.
  28. Stellato M, Cursano MC, Citarella F, Pantano F, Russano M, Dell' Aquila E, Vincenzi B, Tonini G, Santini D. Response to cabozantinib in renal cell carcinoma with cardiac metastases. *Anticancer Drugs*. 2020 Mar;31(3):314-318. doi: 10.1097/CAD.0000000000000889.
  29. Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, Kayal R, Sanguineti G, Marchetti P, Botticelli A, Marinelli D, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Tonini G, Santini D, Michelotti A, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Cazzaniga M, Moscetti L, Fabbri A, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Garufi C, Di Stefano P, Mirabelli R, Veltri E, Paris I, Giotta F, Lorusso V, Landucci E, Ficorella C, Roselli M, Adamo V, Ricciardi G, Russo A, Valerio MR, Berardi R, Pistelli M, Cannita K, Zamagni C, Garrone O, Baldini E, Livi L, Meattini I, Del Medico P, Generali D, De Maria R, Risi E, Ciliberto G, Villa A, Sperduti I, Mazzotta M, Barba M, Giordano A, Vici P. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. *J Cell Physiol*. 2020 Jan 15. doi: 10.1002/jcp.29445.
  30. Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni S, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadri S, Roca E, Vasile E, Imperatori M, Occhipinti M, Galvano A, Petrelli F, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR, Tonini G, Santini D, Adamo V. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. *Adv Ther*. 2020 Mar;37(3):1145-1155. doi: 10.1007/s12325-020-01229-w.
  31. Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. *Eur J Cancer*. 2020 Feb 4;128:17-26. doi: 10.1016/j.ejca.2019.12.031.
  32. Citarella F, Russano M, Pantano F, Dell'Aquila E, Vincenzi B, Tonini G, Santini D. Facing SARS-CoV-2 outbreak in immunotherapy era. *Future Oncol*. 2020 May 29;10.2217/fon-2020-0340. doi: 10.2217/fon-2020-0340.



33. Santini D, Tonini G. Brief letter of a doctor to his psychologist in the COVID-19 outbreak era. *ESMO Open*. 2020 May;5(3):e000801. doi: 10.1136/esmooopen-2020-000801.
34. Napolitano A, Provenzano S, Colombo C, Vitellaro M, Brunello A, Badalamenti G, Nannini M, Ibrahim T, Hohenberger P, Gasperoni S, Gennatas S, Jones RL, Hindi N, Martin-Broto J, Spalato Ceruso M, Silletta M, Dei Tos AP, Gronchi A, Stacchiotti S, Santini D, Tonini G, Palassini E, Vincenzi B. Familial adenomatous polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. *ESMO Open*. 2020 Jan;5(1):e000604. doi: 10.1136/esmooopen-2019-000604.
35. Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, Pantano F, Dell'Aquila E, Anesi C, Silvestris N, Argentiero A, Solimando A, Vincenzi B, Tonini G, Santini D. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. *J Exp Clin Cancer Res*. 2020 May 27;39(1):95. doi: 10.1186/s13046-020-01601-2.
36. Catalano V, Bergamo F, Cremolini C, Vincenzi B, Negri F, Giordani P, Alessandrini P, Intini R, Stragliotto S, Rossini D, Borelli B, Santini D, Sarti D, Rocchi MBL, Lonardi S, Falcone A, Zagonel V, Mattioli R, Graziano F. Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. *J Cancer Res Clin Oncol*. 2020 Feb;146(2):493-501. doi: 10.1007/s00432-019-03077-w.
37. Silipigni S, Ippolito E, Matteucci P, Santo B, Gangemi E, La Cesa A, Santini D, Greco C, Ramella S. Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report. *Breast J*. 2020 Apr 11. doi: 10.1111/tbj.13844.
38. Pantano F, Rossi E, Iuliani M, Facchinetti A, Simonetti S, Ribelli G, Zoccoli A, Vincenzi B, Tonini G, Zamarchi R, Santini D. Dynamic changes of Receptor activator of nuclear factor- $\kappa$ B expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. *Sci Rep*. 2020 Jan 28;10(1):1288. doi: 10.1038/s41598-020-58339-2
39. Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fagnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C. Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. *Oncoimmunology*. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389.
40. Rossini D, Germani MM, Pagani F, Pellino A, Dell'Aquila E, Bensi M, Liscia N, Moretto R, Boccaccino A, Prisciandaro M, Manglaviti S, Schirripa M, Vivolo R, Scartozzi M, Santini D, Salvatore L, Pietrantonio F, Loupakis F, Falcone A, Cremolini C. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. *Clin Colorectal Cancer*. 2020 Apr 11:S1533-0028(20)30046-3. doi: 10.1016/j.clcc.2020.03.009.
41. Ruzzo A, Graziano F, Bagaloni I, Di Bartolomeo M, Prisciandaro M, Aprile G, Ongaro E, Vincenzi B, Perrone G, Santini D, Fornaro L, Vivaldi C, Tomasello G, Loupakis F, Lonardi S, Fassan M, Valmasoni M, Sarti D, Lorenzini P, Catalano V, Bisonni R, Del Prete M, Collina G, Magnani M. Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. *Gastric Cancer*. 2020 May 5. doi:10.1007/s10120-020-01078-0.
42. Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini

- M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fagnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. *Eur J Cancer*. 2020 May 23;134:19-28. doi: 10.1016/j.ejca.2020.04.025.
43. Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari MA, Salvatore L, Tortora G, Rossini D, Germani MM, Boccaccino A, Dell'Aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino PD, Lombardi P, Keränen SR, Álvaro MH, Zurlo IV, Corsi DC, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti MA, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache SD, Porzio G, Ficorella C. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. *Cancers (Basel)*. 2020 May 16;12(5):E1259. doi: 10.3390/cancers12051259.
  44. Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of  $\geq 50$ . *Cancer Immunol Immunother*. 2020 May 30. doi: 10.1007/s00262-020-02613-9.
  45. Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, Vincenzi B. New frontiers in the medical management of gastrointestinal stromal tumours. *Ther Adv Med Oncol*. 2019 May 17;11:1758835919841946. doi:10.1177/1758835919841946.
  46. Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. *JAMA Oncol*. 2019 Mar 1;5(3):343-350. doi:10.1001/jamaoncol.2018.5080.
  47. Schepisi G, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, Cerchione C, Paganelli G, Santini D, Tonini G, Martinelli G, De Giorgi U. CAR-T cell therapy: a potential new strategy against prostate cancer. *J Immunother Cancer*. 2019 Oct 16;7(1):258. doi: 10.1186/s40425-019-0741-7.
  48. Casadei C, Dizman N, Schepisi G, Cursano MC, Basso U, Santini D, Pal SK, De Giorgi U. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. *Ther Adv Med Oncol*. 2019 Nov 25;11:1758835919890285. doi:10.1177/1758835919890285.
  49. Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D, Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliante F, Brandi G, Scarpa A, Cascinu S, Silvestris N. The Italian Rare Pancreatic Exocrine Cancer Initiative. *Tumori*. 2019 Aug;105(4):353-358. doi: 10.1177/0300891619839461. Epub 2019 Apr 9. Erratum in: *Tumori*. 2020 Mar 16;:300891620914460.
  50. Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zaganel V, Fassan M, Di Maio M. A validated

- prognostic classifier for V600E BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. *Eur J Cancer*. 2019 Sep;118:121-130. doi: 10.1016/j.ejca.2019.06.008.
51. Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, Cusenza S, Cutaia S, Santini D, Guadagni F, Roselli M, Gori S, Latteri MA, Bazan V, Giulia LM, Russo A. Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. *J Bone Oncol*. 2019 Jul 16;18:100252. doi: 10.1016/j.jbo.2019.100252.
  52. Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. *J Cell Physiol*. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832.
  53. De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G, Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A, Ercolani G, Santini D, Frassinetti GL, Faloppi L, Scartozzi M, Cascinu S, Casadei-Gardini A. Role of SIRT-3, p-mTOR and HIF-1 $\alpha$  in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. *Int J Mol Sci*. 2019 Mar 26;20(6):1503. doi: 10.3390/ijms20061503.
  54. Santini D, Citarella F, Vincenzi B, Russano M, Tonini G, Stellato M. Cabozantinib and apixaban: an hitherto unreported interaction. *Exp Hematol Oncol*. 2019 Sep 11;8:22. doi: 10.1186/s40164-019-0146-9.
  55. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Carteni G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. *Cancers (Basel)*. 2019 Dec 30;12(1):84. doi: 10.3390/cancers12010084.
  56. Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C. A multicentre study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. *J Immunother Cancer*. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.
  57. Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. *Oncologist*. 2019 Jun;24(6):e327-e337. doi: 10.1634/theoncologist.2018-0618.

58. Procopio G, Pignata S, Altavilla A, Attademo L, De Lisi D, Verzoni E, De Giorgi U, Santini D. Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. *Future Oncol.* 2019 Aug;15(22):2657-2666. doi: 10.2217/fon-2018-0857.
59. Cursano MC, Santini D, Iuliani M, Paganelli G, De Giorgi U. Early use of abiraterone and radium-223 in metastatic prostate cancer. *Lancet Oncol.* 2019 May;20(5):e228. doi: 10.1016/S1470-2045(19)30226-8.
60. Argentiero A, Solimando AG, Brunetti O, Calabrese A, Pantano F, Iuliani M, Santini D, Silvestris N, Vacca A. Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. *Cancers (Basel).* 2019 Aug 29;11(9):1270. doi: 10.3390/cancers11091270.
61. Schepisi G, Brighi N, Cursano MC, Gurioli G, Ravaglia G, Altavilla A, Burgio SL, Testoni S, Menna C, Farolfi A, Casadei C, Tonini G, Santini D, De Giorgi U. Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. *J Oncol.* 2019 Sep 19;2019:7317964. doi: 10.1155/2019/7317964.
62. Roberto M, Botticelli A, Cecere F, Cognetti F, Giusti R, Gelibter A, Lugini A, Nelli F, Nuti M, Santini D, Marchetti P. L'immunoterapia nel tumore del polmone non a piccole cellule: ritorno al futuro [Immunotherapy in non-small cell lung cancer patients: back to the future.]. *Recenti Prog Med.* 2019 Dec;110(12):587-593. Italian. doi: 10.1701/3278.32517.
63. Loupakis F, Bion P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M. CK7 and consensus molecular subtypes as major prognosticators in <sup>V600E</sup>BRAF mutated metastatic colorectal cancer. *Br J Cancer.* 2019 Oct;121(7):593-599. doi: 10.1038/s41416-019-0560-0.
64. Lolli C, De Lisi D, Conteduca V, Gurioli G, Scarpi E, Schepisi G, Ravaglia G, Menna C, Farolfi A, Altavilla A, Burgio SL, Tonini G, Santini D, De Giorgi U. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. *Prostate.* 2019 Aug;79(11):1211-1220. doi: 10.1002/pros.23804.
65. Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti MA, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Porzio G, Ficorella C, Cannita K. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. *J Cancer Res Clin Oncol.* 2019 Sep;145(9):2365-2373. doi: 10.1007/s00432-019-02971-7.
66. Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. *Clin Lung Cancer.* 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.clcc.2019.02.006.
67. Spalato Ceruso M, Napolitano A, Silletta M, Mazzocca A, Valeri S, Improta L, Santini D, Tonini G, Badalamenti G, Vincenzi B. Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients. *Chemotherapy.* 2019;64(2):105-109. doi:10.1159/000501195.
68. Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Torniai M, De Tursi M, Grassadonia A, Di Marino P, Santini D, Zeppola T, Anesi C, Gelibter A, Occhipinti MA, Botticelli A, Marchetti P, Rastelli F, Pergolesi F, Tudini M, Silva RR, Mallardo D, Vanella V, Ficorella C, Porzio G, Ascierto PA. Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. *J Transl Med.* 2019 Nov 15;17(1):376. doi: 10.1186/s12967-019-02132-x.

69. Berardi R, Mastroianni C, Lo Russo G, Buosi R, Santini D, Montanino A, Carnaghi C, Tiseo M, Chiari R, Camerini A, Barni S, De Marino V, Ferrari D, Cristofano A, Doni L, Freddari F, Fumagalli D, Portalone L, Sarmiento R, Schinzari G, Sperandi F, Tucci M, Inno A, Ciuffreda L, Mariotti M, Mariani C, Caramanti M, Torniai M, Gallucci R, Bennati C, Bordi P, Buffoni L, Galeassi A, Ghidini M, Grossi E, Morabito A, Vincenzi B, Arvat E. Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. *Ther Adv Med Oncol*. 2019 Sep 27;11:1758835919877725. doi: 10.1177/1758835919877725.
70. Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P. A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. *RePer Study. Cancer Biol Ther*. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095.
71. Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G. The effect of a treatment delay on outcome in metastatic renal cell carcinoma. *Urol Oncol*. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005.
72. Santini D, Galvano A, Pantano F, Incorvaia L, Rizzo S, Vincenzi B, Castellana L, Giuliana G, Guadagni F, Toia F, Tonini G, Russo A, Badalamenti G, Bazan V. How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. *Crit Rev Oncol Hematol*. 2019 Oct;142:68-75. doi: 10.1016/j.critrevonc.2019.07.013.
73. Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P. Polymorphic Variants in NR113 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study. *Clin Pharmacol Ther*. 2019 Aug;106(2):422-431. doi: 10.1002/cpt.1391.
74. Neuzillet C, Casadei Gardini A, Brieu B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues); GICO (Italian Group of Cholangiocarcinoma) Investigators; Gustave Roussy Institute Cohort; Barts Cancer Institute Cohort. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. *Eur J Cancer*. 2019 Apr;111:94-106. doi: 10.1016/j.ejca.2019.01.019. Epub 2019 Mar 1.
75. De Vincentis G, Frantellizzi V, Follacchio GA, Farcomeni A, Pani A, Samaritani R, Schinzari G, Santini D, Cortesi E. No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium. *Eur J Cancer Care (Engl)*. 2019 Sep;28(5):e13112. doi: 10.1111/ecc.13112.
76. Cazzato RL, Arrigoni F, Boatta E, Bruno F, Chiang JB, Garnon J, Zugaro L, Giordano AV, Carducci S, Varrassi M, Beomonte Zobel B, Bazzocchi A, Aliprandi A, Basile A, Marcia S, Masala S, Grasso RF, Squarza S, Floridi C, Ierardi AM, Burdi N, Cioni R, Napoli A, Niola R, Rossi G, Rossi UG, Venturini M, De Cobelli F, Carotti M, Gravina GL, Di Staso M, Zoccali C, Biagini R, Tonini G, Santini D, Carrafiello G, Cariati M, Silvestri E, Sconfienza LM, Giovagnoni A, Masciocchi C, Gangi A, Barile A. Percutaneous management of bone metastases: state of the art, interventional strategies and joint position statement of the

- Italian College of MSK Radiology (ICoMSKR) and the Italian College of Interventional Radiology (ICIR). *Radiol Med*. 2019 Jan;124(1):34-49. doi:10.1007/s11547-018-0938-8.
77. Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerratana L, Aprile G. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. *J Geriatr Oncol*. 2019 Jul;10(4):591-597. doi: 10.1016/j.jgo.2018.11.009.
  78. Davies AN, Elsner F, Filbet MJ, Porta-Sales J, Ripamonti C, Santini D, Webber K. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines. *BMJ Support Palliat Care*. 2018 Sep;8(3):241-249. doi: 10.1136/bmjspcare-2017-001467.
  79. Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuy F, Taieb J, Stintzing S, Siena S, Santini D. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. *ESMO Open*. 2018 May 5;3(4):e000353. doi: 10.1136/esmoopen-2018-000353.
  80. Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. *J Cell Physiol*. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832.
  81. Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D, Reni M, Cascinu S, Silvestris N. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. *Pancreas*. 2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063.
  82. Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G, Malaguti P, Giannarelli D, Cognetti F. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. *Breast*. 2018 Oct;41:137-143. doi: 10.1016/j.breast.2018.07.004.
  83. De Lisi D, De Giorgi U, Lolli C, Schepisi G, Conteduca V, Menna C, Tonini G, Santini D, Farolfi A. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? *Expert Opin Drug Metab Toxicol*. 2018 Apr;14(4):461-467. doi: 10.1080/17425255.2018.1455826.
  84. Fiore M, D'Apos Angelillo RM, Greco C, Fioroni I, Ippolito E, Santini D, Ramella S. Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer. *Chemotherapy*. 2018 Mar 19;63(2):83-89. doi: 10.1159/000488252.
  85. Santoni M, Piva F, De Giorgi U, Mosca A, Basso U, Santini D, Buti S, Lolli C, Terrone C, Maruzzo M, Iuliani M, Bersanelli M, Conti A, Mazzucchelli R, Montironi R, Burattini L, Berardi R. Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. *Anticancer Res*. 2018 Oct;38(10):5773-5782. doi: 10.21873/anticancer.12916.
  86. Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Carteni G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D,

- Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clin Genitourin Cancer*. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014.
87. Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S, Frassinetti GL, Scartozzi M. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. *Tumori*. 2018 Dec;104(6):476-479. doi: 10.5301/tj.5000704.
  88. Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. *Ther Adv Med Oncol*. 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623.
  89. Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P. A multicenter RETrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. *RePer Study. Cancer Biol Ther*. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095.
  90. Camilli M, Papadimitriou K, Nogueira A, Incorvaia L, Galvano A, D'Antonio F, Ferri J, Santini D, Silvestris N, Russo A, Peeters M, Rolfo C. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. *Expert Rev Gastroenterol Hepatol*. 2018 May;12(5):471-478. doi: 10.1080/17474124.2018.1463157.
  91. Rauh S, Antonuzzo A, Bossi P, Eckert R, Fallon M, Fröbe A, Gonella S, Giusti R, Lakatos G, Santini D, Villarini A. Nutrition in patients with cancer: a new area for medical oncologists? A practising oncologist's interdisciplinary position paper. *ESMO Open*. 2018 May 5;3(4):e000345. doi: 10.1136/esmoopen-2018-000345.
  92. Del Re M, Crucitta S, Restante G, Rofi E, Arrigoni E, Biasco E, Sbrana A, Coppi E, Galli L, Bracarda S, Santini D, Danesi R. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. *Crit Rev Oncol Hematol*. 2018 May;125:51-59. doi: 10.1016/j.critrevonc.2018.03.002.
  93. Sbrana A, Biasco E, Paolieri F, Palesandro E, Caserta C, Iacovelli R, Detti B, Santini D, Mosca A, Morelli F, Fornarini G, De Giorgi U, Masini C, Galli L. Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. *Anticancer Res*. 2018 Aug;38(8):4913-4918. doi: 10.21873/anticancer.12807.
  94. Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. *Anticancer Drugs*. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632.
  95. Conteduca V, Caffo O, Galli L, Maugeri A, Scarpi E, Maines F, Chiuri VE, Lolli C, Kinspergher S, Schepisi G, Santoni M, Santini D, Fratino L, Burgio SL, Salvi S, Menna C, De Giorgi U. Association among metabolic syndrome, inflammation, and survival in prostate cancer. *Urol Oncol*. 2018 May;36(5):240.e1-240.e11. doi: 10.1016/j.urolonc.2018.01.007.

96. Pietrantonio F, Barretta F, Fanotto V, Park SH, Morano F, Fucà G, Nigam M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G. Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. *Oncology*. 2018;95(6):344-352. doi: 10.1159/000491753.
97. Vincenzi B, Badalamenti G, Armento G, Silletta M, Spalato Ceruso M, Catania G, Napolitano A, Maltese G, Valeri S, Incorvaia L, Santini D, Tonini G. Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. *Oncology*. 2018;95(1):1-7. doi: 10.1159/000487266.
98. Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? *Clin Genitourin Cancer*. 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007.
99. Vitale MG, Scagliarini S, Galli L, Pignata S, Lo Re G, Berruti A, Defferrari C, Spada M, Masini C, Santini D, Ciuffreda L, Ruggeri EM, Bengala C, Livi L, Fagnani D, Bonetti A, Giustini L, Hamzaj A, Procopio G, Caserta C, Sabbatini R. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. *PLoS One*. 2018 Jul 6;13(7):e0199642. doi: 10.1371/journal.pone.0199642.
100. Cortellini A, Coccione V, Irelli A, Pavese F, Sidoni T, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Bonfili P, Franzese P, Zugaro L, Verna L, Porzio G, Santini D, Cannita K, Ficorella C. The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice. *Oncol Lett*. 2018 Dec;16(6):7195-7203. doi: 10.3892/ol.2018.9561.
101. Calabrese V, Menna P, Annibaldi O, Armento G, Carpino A, Cerchiara E, Greco C, Marchesi F, Spallarossa P, Togliola G, Reggiardo G, Minotti G; Collaborators. Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. *Chemotherapy*. 2018;63(2):55-63. doi: 10.1159/000486761. Epub 2018 Feb 9. Erratum in: *Chemotherapy*. 2018 Apr;63(2):64.
102. Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G (2017). Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. *THE ONCOLOGIST*, vol. 22, p. 1463-1469, ISSN: 1083-7159, doi: 10.1634/theoncologist.2017-0158
103. Lucchesi M, Lanzetta G, Antonuzzo A, Rozzi A, Sardi I, Favre C, Ripamonti CI, Santini D, Armento G (2017). Developing drugs in cancer-related bone pain. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*, vol. 119, p. 66-74, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2017.08.005
104. Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Torri V, Aprile G (2017). Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. *GASTRIC CANCER*, vol. 20, p. 825-833, ISSN: 1436-3291, doi: 10.1007/s10120-016-0681-6
105. Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Di Filippo S, Di Lauro L, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Sacca M, Barba M, Vici P (2017). Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The



- EverExt study. SCIENTIFIC REPORTS, vol. 7, ISSN: 2045-2322, doi: 10.1038/s41598-017-10061-2
106. Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F (2017). Efficacy and safety of T-DM1 in the 'common-practice' of HER2+advanced breast cancer setting: a multicenter study. ONCOTARGET, vol. 8, p. 64481-64489, ISSN: 1949-2553, doi: 10.18632/oncotarget.16373
  107. Gardini AC, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzone M, Silletta M, Brunetti O, Cardellino GG, Frassinetti GL, Scartozzi M (2017). Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. ONCOTARGET, vol. 8, p. 66699-66708, ISSN: 1949-2553, doi: 10.18632/oncotarget.19449
  108. Vincenzi B, Badalamenti G, Napolitano A, Ceruso MS, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G (2017). Olaratumab: PDGFR-alpha inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 118, p. 1-6, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2017.06.006
  109. Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G (2017). Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. FUTURE ONCOLOGY, vol. 13, p. 2265-2275, ISSN: 1479-6694, doi: 10.2217/fo-2017-0246
  110. Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G (2017). Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? (vol 23, pg 2313, 2012). ANNALS OF ONCOLOGY, vol. 28, p. 2906, ISSN: 0923-7534, doi: 10.1093/annonc/mdw551
  111. Gardini AC, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassinetti GL, Scartozzi M (2017). Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. EUROPEAN JOURNAL OF CANCER, vol. 86, p. 106-114, ISSN: 0959-8049, doi: 10.1016/j.ejca.2017.09.003
  112. Baldari S, Boni G, Bortolus R, Caffo O, Conti G, De Vincentis G, Monari F, Procopio G, Santini D, Seregni E, Valdagni R (2017). Management of metastatic castration-resistant prostate cancer: A focus on radium-223 Opinions and suggestions from an expert multidisciplinary panel. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 113, p. 43-51, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2017.03.001
  113. Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, Gori S, Tonini G, Barone C (2017). A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. BRITISH JOURNAL OF CANCER, vol. 116, p. 1279-1286, ISSN: 0007-0920, doi: 10.1038/bjc.2017.109
  114. Longo V, Gnoni A, Gardini AC, Pisconti S, Licchetta A, Scartozzi M, Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O (2017). Immunotherapeutic approaches for hepatocellular carcinoma. ONCOTARGET, vol. 8, p. 33897-33910, ISSN: 1949-2553, doi: 10.18632/oncotarget.15406

115. Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A (2017). TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. *BMC CANCER*, vol. 17, ISSN: 1471-2407, doi: 10.1186/s12885-017-3360-z
116. Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, Scartozzi M (2017). Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*, vol. 115, p. 1-12, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2017.03.025
117. Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G (2017). Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. *BRITISH JOURNAL OF CANCER*, vol. 117, p. 340-346, ISSN: 0007-0920, doi: 10.1038/bjc.2017.187
118. De Matteis S, Granato AM, Napolitano R, Molinari C, Valgiusti M, Santini D, Foschi FG, Ercolani G, Gentilucci UV, Faloppi L, Scartozzi M, Frassinetti GL, Gardini AC (2017). Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. *DIGESTIVE DISEASES AND SCIENCES*, vol. 62, p. 1872-1880, ISSN: 0163-2116, doi: 10.1007/s10620-017-4615-x
119. Bertani FR, Mozetic P, Fioramonti M, Iuliani M, Ribelli G, Pantano F, Santini D, Tonini G, Trombetta M, Businaro L, Selci S, Rainer A (2017). Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis. *SCIENTIFIC REPORTS*, vol. 7, ISSN: 2045-2322, doi: 10.1038/s41598-017-08121-8
120. Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Sacca M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T (2017). A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. *ONCOTARGET*, vol. 8, p. 56921-56931, ISSN: 1949-2553, doi: 10.18632/oncotarget.18176
121. Manca P, Russano M, Pantano F, Tonini G, Santini D (2017). Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib. *ONCOTARGET*, vol. 8, p. 59986-59990, ISSN: 1949-2553, doi: 10.18632/oncotarget.17607
122. Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, Gori S, Tonini G, Barone C (2017). A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. *BRITISH JOURNAL OF CANCER*, vol. 116, p. 1279-1286, ISSN: 0007-0920, doi: 10.1038/bjc.2017.109
123. von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D (2017). Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. *EUROPEAN JOURNAL OF CANCER*, vol. 71, p. 80-94, ISSN: 0959-8049, doi: 10.1016/j.ejca.2016.10.021
124. Amato M, Perrone G, Righi D, Pellegrini C, Rabitti C, Di Matteo F, Crucitti P, Caputo D, Coppola R, Tonini G, Santini D, Muda AO (2017). HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. *PATHOLOGY*

- ONCOLOGY RESEARCH, vol. 23, p. 55-61, ISSN: 1219-4956, doi: 10.1007/s12253-016-0082-5
125. Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M, Brunetti O, Scartozzi M, Santini D, Silvestris N, Gardini AC, Puzzone M, Calvetti L, Cardarelli N, Aprile G (2017). Immunotherapy for colorectal cancer: where are we heading?. EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 17, p. 709-721, ISSN: 1471-2598, doi: 10.1080/14712598.2017.1315405
  126. Fioramonti M, Santini D, Iuliani M, Ribelli G, Manca P, Papapietro N, Spiezia F, Vincenzi B, Denaro V, Russo A, Tonini G, Pantano F (2017). Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. ONCOTARGET, vol. 8, p. 20113-20121, ISSN: 1949-2553, doi: 10.18632/oncotarget.15390
  127. Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, Bracarda S, Santini D, Danesi R (2017). The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. CANCER TREATMENT REVIEWS, vol. 55, p. 71-82, ISSN: 0305-7372, doi: 10.1016/j.ctrv.2017.03.001
  128. Manca P, Pantano F, Iuliani M, Ribelli G, De Lisi D, Danesi R, Del Re M, Vincenzi B, Tonini G, Santini D (2017). Determinants of bone specific metastasis in prostate cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 112, p. 59-66, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2017.02.013
  129. Rizzo S, Galvano A, Pantano F, Iuliani M, Vincenzi B, Passiglia F, Spoto S, Tonini G, Bazan V, Russo A, Santini D (2017). The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 120, p. 227-233, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2017.09.008
  130. Maugeri-Sacca M, Barba M, Vici P, Pizzuti L, Sergi D, Catenaro T, Di Lauro L, Mottolose M, Santini D, Milella M, De Maria R (2016). Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 106, p. 132-142, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2016.08.004
  131. Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, Mosconi S, Vasile E, Santini D, Belli C, Auriemma A, Novarino A, Vaccaro V, Martines C, Marino D, Lutrino SE, Palazzo V, Reinach B, Aldrighetti L, Reni M (2016). Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 77, p. 109-114, ISSN: 0344-5704, doi: 10.1007/s00280-015-2919-0
  132. Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E (2016). Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. FUTURE ONCOLOGY, vol. 12, p. 493-502, ISSN: 1479-6694, doi: 10.2217/fon.15.302
  133. Fusco V, Santini D, Armento G, Tonini G, Campisi G (2016). Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. EXPERT OPINION ON DRUG SAFETY, vol. 15, p. 925-935, ISSN: 1474-0338, doi: 10.1080/14740338.2016.1177021
  134. Vincenzi B, Armento G, Ceruso Spalato M, Catania G, Lealos M, Santini D, Minotti G, Tonini G (2016). Drug-induced hepatotoxicity in cancer patients - implication for treatment. EXPERT OPINION ON DRUG SAFETY, vol. 15, p. 1219-1238, ISSN: 1474-0338, doi: 10.1080/14740338.2016.1194824

135. Borro M, Simmaco M, Aceti A, Barni S, De Luca A, Fineschi V, Frati P, Girardi P, Miozzo M, Nati G, Nicoletti F, Santini D, Marchetti P (2016). H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine. *CURRENT PHARMACEUTICAL BIOTECHNOLOGY*, vol. 17, p. 926-929, ISSN: 1389-2010, doi: 10.2174/1389201017666160519112850
136. Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, Licitra L, Montironi R, Tortora G, Massari F (2016). New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. *EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY*, vol. 12, p. 57-75, ISSN: 1742-5255, doi: 10.1517/17425255.2016.1120287
137. Silvestris N, Longo V, Cellini F, Reni M, Bittoni A, Cataldo I, Partelli S, Falconi M, Scarpa A, Brunetti O, Lorusso V, Santini D, Morganti A, Valentini V, Cascinu (2016). Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*, vol. 98, p. 309-324, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2015.11.016
138. Massari F, Modena A, Ciccarese C, Pilotto S, Maines F, Bracarda S, Sperduti I, Giannarelli D, Carlini P, Santini D, Tortora G, Porta C, Bria E (2016). Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*, vol. 98, p. 254-263, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2015.11.009
139. Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M (2016). Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 34, p. 436-U99, ISSN: 0732-183X, doi: 10.1200/JCO.2015.61.0733
140. Hadji P, Coleman RE, Wilson C, Powles TJ, Clezardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnani M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I (2016). Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. *ANNALS OF ONCOLOGY*, vol. 27, p. 379-390, ISSN: 0923-7534, doi: 10.1093/annonc/mdv617
141. Santini D, Tonini G (2016). Treatment of Advanced Renal-Cell Carcinoma. *NEW ENGLAND JOURNAL OF MEDICINE*, vol. 374, p. 888-889, ISSN: 0028-4793
142. Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Sacca M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F (2016). "Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. *ONCOTARGET*, vol. 7, p. 17932-17944, ISSN: 1949-2553
143. Faloppi L, Del Prete M, Gardini AC, Santini D, Silvestris N, Bianconi M, Giampieri R, Valgiusti M, Brunetti O, Bittoni A, Andrikou K, Lai E, Dessi A, Cascinu S, Scartozzi M (2016). The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. *SCIENTIFIC REPORTS*, vol. 6, ISSN: 2045-2322, doi: 10.1038/srep24136
144. Passiglia F, Bronte G, Bazan V, Natoli C, Rizzo S, Galvano A, Listi A, Cicero G, Rolfo C, Santini D, Russo A (2016). PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. *ONCOTARGET*, vol. 7, p. 19738-19747, ISSN: 1949-2553
145. Santini D, Barni S, Intagliata S, Falcone A, Ferrau F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collova E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F,

- Vincenzi B, Tonini G (2016). Natural History of Non-Small-Cell Lung Cancer with Bone Metastases (vol 5, 18670, 2015). SCIENTIFIC REPORTS, vol. 6, ISSN: 2045-2322, doi: 10.1038/srep22205
146. Fanale D, Amodeo V, Bazan V, Insalaco L, Incorvaia L, Barraco N, Castiglia M, Rizzo S, Santini D, Giordano A, Castorina S, Russo A (2016). Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. ONCOTARGET, vol. 7, p. 29321-29332, ISSN: 1949-2553, doi: 10.18632/oncotarget.8722
  147. Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G (2016). Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. ONCOTARGET, vol. 7, p. 40085-40094, ISSN: 1949-2553, doi: 10.18632/oncotarget.9485
  148. Gori S, Inno A, Rossi V, Turazza M, Fiorio E, Fabi A, Bisagni G, Foglietta J, Santini D, Pavese I, Pellegrino A, Zambelli A, Vici P, Leonardi V, Barni S, Saracchini S, Bogina G, Marchetti F, Duranti S, Lunardi G, Montemurro F (2016). Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. PLOS ONE, vol. 11, ISSN: 1932-6203, doi: 10.1371/journal.pone.0156221
  149. Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G (2016). Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. ONCOTARGET, vol. 7, p. 33381-33390, ISSN: 1949-2553, doi: 10.18632/oncotarget.8302
  150. Vincenzi B, Fioroni I, Pantano F, Angeletti S, Dicuonzo G, Zoccoli A, Santini D, Tonini G (2016). Procalcitonin as diagnostic marker of infection in solid tumors patients with fever. SCIENTIFIC REPORTS, vol. 6, ISSN: 2045-2322, doi: 10.1038/srep28090
  151. Gardini AC, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G, Frassinetti GL (2016). Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. ONCOTARGET, vol. 7, p. 67142-67149, ISSN: 1949-2553, doi: 10.18632/oncotarget.11565
  152. Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Ceruso MS, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos A, Casali P, Tonini G (2016). Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. ONCOTARGET, vol. 7, p. 69412-69419, ISSN: 1949-2553, doi: 10.18632/oncotarget.5136
  153. Sartore-Bianchi A, Siena S, Tonini G, Bardelli A, Santini D (2016). Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. CANCER TREATMENT REVIEWS, vol. 51, p. 54-62, ISSN: 0305-7372, doi: 10.1016/j.ctrv.2016.10.006
  154. Santoni M, Scarpelli M, Lopez-Beltran A, Cheng L, Briganti A, Montorsi F, Montironi R, Santini D (2016). Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3. EUROPEAN UROLOGY, vol. 70, p. E69-E70, ISSN: 0302-2838, doi: 10.1016/j.eururo.2015.09.022
  155. Fusco V, Campisi G, Numico G, Migliorati CA, Santini D, Bedogni A (2016). RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw. JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 108, ISSN: 0027-8874, doi: 10.1093/jnci/djw155
  156. Puzzone M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, Ongaro E, Astaro G, Orgiano L, Aprile G, Santini D,

- Scartozzi M (2016). The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. *TARGETED ONCOLOGY*, vol. 11, p. 593-603, ISSN: 1776-2596, doi: 10.1007/s11523-016-0437-6
157. Moscetti L, Vici P, Gamucci T, Natoli C, Cortesi E, Marchetti P, Santini D, Giuliani R, Sperduti I, Mauri M, Pizzuti L, Mancini ML, Fabbri MA, Magri V, Iezzi L, Sini V, D'Onofrio L, Mentuccia L, Vaccaro A, Ramponi S, Roma CL, Ruggeri EM (2016). Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. *THE BREAST*, vol. 29, p. 96-101, ISSN: 0960-9776, doi: 10.1016/j.breast.2016.07.005
158. Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-Sacca M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, Sanguineti G, Giordano A, De Maria R, Venuti A (2016). Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. *EXPERT REVIEW OF VACCINES*, vol. 15, p. 1327-1336, ISSN: 1476-0584, doi: 10.1080/14760584.2016.1176533
159. Santoni M, Massari F, Del Re M, Ciccarese C, Piva F, Principato G, Montironi R, Santini D, Danesi R, Tortora G, Cascinu S. (2015). Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.. *EXPERT OPINION ON INVESTIGATIONAL DRUGS*, vol. 24(6), p. 809-824, ISSN: 1354-3784, doi: 10.1517/13543784.2015.1020370
160. Cazzato RL, Palussière J, Buy X, Denaro V, Santini D, Tonini G, Grasso RF, Zobel BB, Poretti D, Pedicini V, Balzarini L, Lanza E. (2015). Percutaneous Long Bone Cementoplasty for Palliation of Malignant Lesions of the Limbs: A Systematic Review.. *CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY*, ISSN: 0174-1551
161. Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P, Sliva D, Subbarayan PR, Sarkar M, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Ye L, Helferich WG, Yang X, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Nowsheen S, Pantano F, Santini D (2015). Tissue invasion and metastasis: Molecular, biological and clinical perspectives.. *SEMINARS IN CANCER BIOLOGY*, ISSN: 1044-579X, doi: 10.1016/j.semcancer.2015.03.008
162. Grimaldi A, Santini D, Zappavigna S, Lombardi A, Misso G, Boccellino M, Desiderio V, Vitiello PP, Di Lorenzo G, Zoccoli A, Pantano F, Caraglia M. (2015). Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells.. *CANCER BIOLOGY & THERAPY*, vol. 16(4), p. 567-579, ISSN: 1538-4047, doi: 10.1080/15384047.2015.1018494
163. Fioroni I, Dell'Aquila E, Pantano F, Intagliata S, Caricato M, Vincenzi B, Coppola R, Santini D, Tonini G. (2015). Role of c-mesenchymal-epithelial transition pathway in gastric cancer.. *EXPERT OPINION ON PHARMACOTHERAPY*, vol. 16(8), p. 1195-1207, ISSN: 1465-6566, doi: 10.1517/14656566.2015.1037739
164. Venditti O, De Lisi D, Caricato M, Caputo D, Capolupo GT, Taffon C, Pagliara E, Battisi S, Frezza AM, Onetti Muda A, Tonini G, Santini D (2015). Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis.. *BMC CANCER*, vol. 15, ISSN: 1471-2407, doi: 10.1186/s12885-015-1074-7.
165. Pantano F, Santoni M, Procopio G, Rizzo M, Iacovelli R, Porta C, Conti A, Lugini A, Milella M, Galli L, Ortega C, Guida FM, Silletta M, Schinzari G, Verzoni E, Modica D, Crucitti P, Rauco A, Felici A, Ballatore V, Cascinu S, Tonini G, Carteni G, Russo A, Santini D (2015). The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. *PLOS ONE*, vol. 10(4), ISSN: 1932-6203, doi: 10.1371/journal.pone.0120427
166. Vincenzi B, Iuliani M, Zoccoli A, Pantano F, Fioramonti M, De Lisi D, Frezza AM, Rabitti C, Perrone G, Onetti Muda A, Russo A, Giordano A, Santini D, Dei Tos AP, Tonini G. (2015). Deregulation of dicer and mir-155 expression in liposarcoma.. *ONCOTARGET*, vol. 6(12), p. 10586-10591, ISSN: 1949-2553

167. Vincenzi B, Iuliani M, Zoccoli A, Pantano F, Fioramonti M, De Lisi D, Frezza AM, Rabitti C, Perrone G, Onetti Muda A, Russo A, Giordano A, Santini D, Dei Tos AP, Tonini G. (2015). Classic Kaposi Sarcoma: to treat or not to treat? . BMC RESEARCH NOTES, vol. 8, ISSN: 1756-0500, doi: 10.1186/s13104-015-1076-1.
168. Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, Zoccoli A, Ribelli G, Tucci M, Vignani F, Berruti A, Scagliotti GV, Tonini G, Santini D (2015). Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment.. ONCOTARGET, ISSN: 1949-2553
169. Bronte G, Rolfo C, Passiglia F, Rizzo S, Gil-Bazo I, Fiorentino E, Cajozzo M, Van Meerbeeck JP, Lequaglie C, Santini D, Pauwels P, Russo A. (2015). What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis.. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2015.03.010
170. Russano M, Vincenzi B, Venditti O, D'Onofrio L, Ratta R, Guida FM, Tonini G, Santini D (2015). Pazopanib and pancreatic toxicity: a case report. . BMC RESEARCH NOTES, vol. 8(1), ISSN: 1756-0500, doi: 10.1186/s13104-015-1154-4.
171. Scartozzi M, Giampieri R, Aprile G, Iacono D, Santini D, dell'Aquila E, Silvestris N, Gnoni A, Bonotto M, Puzoni M, Demurtas L, Cascinu S. (2015). The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. . EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, p. 1-9, ISSN: 1473-7159
172. Di Lauro L, Pizzuti L, Barba M, Sergi D, Sperduti I, Mottolese M, Amoreo CA, Belli F, Vici P, Speirs V, Santini D, De Maria R, Maugeri-Saccà M. (2015). Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. . JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 8(1), ISSN: 1756-8722, doi: 10.1186/s13045-015-0147-z.
173. Conteduca V, Caffo O, Derosa L, Veccia A, Petracci E, Chiuri VE, Santoni M, Santini D, Fratino L, Maines F, Testoni S, De Giorgi U. (2015). Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. . PROSTATE, ISSN: 0270-4137, doi: 10.1002/pros.23014
174. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Luceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Hui R, Chu Q, Leighl N, Chomy F, Dansin E, Lena H, Quere G, Soria JC, Cappuzzo F, Garassino M, Melotti B, Morabito A, Santini D, Brunsvig P, Fløtten Ø, Ahn MJ, Lee DH, Lee JS, Carcereny E, Felip E, Insa A, Yang JC, Tsai CM, Arkenau HT, Grummet S, Middleton G, Aggarwal C, Balmanoukian AS, Bessudo A, Blumenschein GR Jr, Dronca R, Eder JP, Garon EB, Gandhi L, Goldman J, Gubens M, Hager S, Hamid O, Hellmann MD, Horn L, Johnson E, O'Day S, Patnaik A, Ramalingam S, Rizvi NA, Ross H, Socinski M. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer.. NEW ENGLAND JOURNAL OF MEDICINE, vol. 372(21), p. 2018-2028, ISSN: 0028-4793, doi: 10.1056/NEJMoa1501824
175. Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. (2015). Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.. THE JOURNAL OF UROLOGY, vol. 193(1), p. 41-47, ISSN: 0022-5347, doi: 10.1016/j.juro.2014.07.011.
176. Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. (2015). Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 93(1), p. 50-59, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2014.08.001.

177. Berardi R, Rinaldi S, Santini D, Vincenzi B, Giampieri R, Maccaroni E, Marcucci F, Francoletti M, Onofri A, Lucarelli A, Pierantoni C, Tonini G, Cascinu S. (2015). Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis.. *SUPPORTIVE CARE IN CANCER*, vol. 23(5), p. 1295-1302, ISSN: 0941-4355, doi: 10.1007/s00520-014-2466-y
178. Silvestris N, Scartozzi M, Graziano G, Santini D, Lorusso V, Maiello E, Barni S, Cinieri S, Loupakis F, Pisconti S, Brunetti AE, Palasciano G, Palmieri VO, Del Prete M, Dell'Aquila E, Latiano TP, Petrelli F, Lutrino S, Rossini D, Giampieri R, Lotesoriere C, Cascinu S. (2015). Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.. *EXPERT OPINION ON BIOLOGICAL THERAPY*, vol. 15(2), p. 155-162, ISSN: 1471-2598, doi: 10.1517/14712598.2015.986452.
179. Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. (2015). Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.. *ANNALS OF SURGICAL ONCOLOGY*, vol. 22(6), p. 2094-2100, ISSN: 1068-9265, doi: 10.1245/s10434-014-4256-7.
180. Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. (2015). Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.. *TARGETED ONCOLOGY*, ISSN: 1776-2596
181. Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S. (2015). Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.. *CANCER TREATMENT REVIEWS*, vol. 41(2), p. 136-143, ISSN: 0305-7372, doi: 10.1016/j.ctrv.2014.12.003.
182. Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G. (2015). PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.. *CANCER TREATMENT REVIEWS*, vol. 41(2), p. 114-121, ISSN: 0305-7372, doi: 10.1016/j.ctrv.2014.12.013.
183. Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, Montironi R, Santini D, Cheng L, Martignoni G, Cascinu S, Tortora G. (2015). The route to personalized medicine in bladder cancer: where do we stand?. *TARGETED ONCOLOGY*, ISSN: 1776-2596
184. Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, Santini D (2015). Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 34(1), ISSN: 1756-9966, doi: 10.1186/s13046-015-0122-0.
185. Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, Pisconti S, Petrelli F, Vacca A, Lorusso V. (2015). Metronomic chemotherapy from rationale to clinical studies: A dream or reality?. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2015.01.008
186. Palmer C, Santini D (2015). A key opinion leader interview with Prof D Santini: insight into cancer research.. *EXPERT OPINION ON THERAPEUTIC TARGETS*, vol. 19(3), p. 443-445, ISSN: 1472-8222, doi: 10.1517/14728222.2015.1015227



187. Lastraioli E, Perrone G, Sette A, Fiore A, Crociani O, Manoli S, D'Amico M, Masselli M, Iorio J, Callea M, Borzomati D, Nappo G, Bartolozzi F, Santini D, Bencini L, Farsi M, Boni L, Di Costanzo F, Schwab A, Onetti Muda A, Coppola R, Arcangeli A. (2015). hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.. *BRITISH JOURNAL OF CANCER*, vol. 112(6), p. 1076-1087, ISSN: 0007-0920, doi: 10.1038/bjc.2015.28.
188. Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E. (2014). Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.. *EUROPEAN UROLOGY*, ISSN: 0302-2838, doi: 10.1016/j.eururo.2014.10.014.
189. Taffurelli M, Montroni I, Santini D, Fiacchi M, Zanotti S, Ugolini G, Serra M, Rosati G. (2014). Reply to letter: "effectiveness of sentinel lymph node intraoperative examination in 753 women with breast cancer: are we overtreating patients?". *ANNALS OF SURGERY*, vol. 259(4), ISSN: 0003-4932, doi: 10.1097/SLA.0000000000000473
190. Montroni I, Rocchi M, Santini D, Ceccarelli C, Ghignone F, Zattoni D, Nuvola G, Zanotti S, Ugolini G, Taffurelli M. (2014). Has breast cancer in the elderly remained the same over recent decades? A comparison of two groups of patients 70years or older treated for breast cancer twenty years apart.. *JOURNAL OF GERIATRIC ONCOLOGY*, vol. 5(3), p. 260-265, ISSN: 1879-4068, doi: 10.1016/j.jgo.2014.02.006.
191. Vici P, Pizzuti L, Natoli C, Moscetti L, Mentuccia L, Vaccaro A, Sergi D, Di Lauro L, Trenta P, Seminara P, Santini D, Iezzi L, Tinari N, Bertolini I, Sini V, Mottolese M, Giannarelli D, Giotta F, Maugeri-Saccà M, Barba M, Marchetti P, Michelotti A, Sperduti I, Gamucci T. (2014). Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.. *BREAST CANCER RESEARCH AND TREATMENT*, vol. 147(3), p. 599-607, ISSN: 0167-6806, doi: 10.1007/s10549-014-3133-1
192. Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, Andreis D, Venturini S, Brugnoli G, Petronini PG, Zanoni V, Pritzker L, Pritzker K, Parissenti A, Santini D, Fox SB, Bottini A, Generali D. (2014). Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".. *BREAST CANCER RESEARCH AND TREATMENT*, vol. 144(1), p. 113-121, ISSN: 0167-6806, doi: 10.1007/s10549-014-2840-y.
193. Santoni M, Pantano F, Amantini C, Nabissi M, Conti A, Burattini L, Zoccoli A, Berardi R, Santoni G, Tonini G, Santini D, Cascinu S. (2014). Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.. *BIOCHIMICA ET BIOPHYSICA ACTA*, vol. 1845(2), p. 221-231, ISSN: 0006-3002, doi: 10.1016/j.bbcan.2014.01.007
194. Ripamonti CI, Bossi P, Santini D, Fallon M. (2014). Pain related to cancer treatments and diagnostic procedures: a no man's land?. *ANNALS OF ONCOLOGY*, vol. 25(6), p. 1097-1106, ISSN: 0923-7534, doi: 10.1093/annonc/mdl011.
195. Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G. (2014). Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.. *BRITISH JOURNAL OF CANCER*, vol. 110(9), p. 2165-2169, ISSN: 0007-0920, doi: 10.1038/bjc.2014.

196. Fanale D, Iovanna JL, Calvo EL, Berthezene P, Belleau P, Dagorn JC, Bronte G, Cicero G, Bazan V, Rolfo C, Santini D, Russo A. (2014). Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?. EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 18(8), p. 841-850, ISSN: 1472-8222, doi: 10.1517/14728222.2014.920324
197. Battisti S, Guida FM, Coppa F, Vaccaro DM, Santini D, Tonini G, Zobel BB, Semelka RC. (2014). Modification of abdominal fat distribution after aromatase inhibitor therapy in breast cancer patients visualized using 3-D computed tomography volumetry.. CLINICAL BREAST CANCER, vol. 14(5), p. 365-370, ISSN: 1526-8209, doi: 10.1016/j.clbc.2014.02.003.
198. Ratta R, Santini D (2014). Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.. TUMORI, vol. 100(2), p. e59-e62, ISSN: 0300-8916, doi: 10.1700/1491.16441.
199. Ruzzo A, Catalano V, Canestrari E, Giacomini E, Santini D, Tonini G, Vincenzi B, Fiorentini G, Magnani M, Graziano F. (2014). Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.. BMC CANCER, vol. 14, ISSN: 1471-2407, doi: 10.1186/1471-2407-14-357.
200. Passiglia F, Van Der Steen N, Racz L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, Cappuzzo F, Rolfo C. (2014). The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?. CURRENT DRUG TARGETS, vol. 15(14), p. 1284-1292, ISSN: 1389-4501
201. Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, Taverna S, Vento R, Santini D, Peeters M, Russo A, Pauwels P. (2014). Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546].. BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1855(1), ISSN: 0006-3002, doi: 10.1016/j.bbcan.2014.11.003.
202. Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D (2014). Targeting bone metastatic cancer: Role of the mTOR pathway. . BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1845, p. 248-254, ISSN: 0006-3002, doi: 10.1016/j.bbcan.2014.01.009
203. Scartozzi Mario, Giampieri Riccardo, Del Prete Michela, Faloppi Luca, Bianconi Maristella, Vincenzi Bruno, Tonini Giuseppe, Santini D, Cascinu Stefano (2014). Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. EXPERT OPINION ON PHARMACOTHERAPY, vol. 15, p. 143-150, ISSN: 1465-6566, doi: 10.1517/14656566.2014.860964
204. Silvestris Nicola, Gnoni Antonio, Brunetti Anna Elisabetta, Vincenti Leonardo, Santini D, Tonini Giuseppe, Merchionne Francesca, Maiello Evaristo, Lorusso Vito, Nardulli Patrizia, Azzariti Amalia, Reni Michele (2014). Target Therapies in Pancreatic Carcinoma. CURRENT MEDICINAL CHEMISTRY, vol. 21, p. 948-965, ISSN: 0929-8673
205. Croset M, Santini D, Iuliani M, Fioramonti M, Zoccoli A, Vincenzi B, Tonini G, Pantano F. (2014). MicroRNAs and bone metastasis: a new challenge.. MOLECULES, vol. 19(7), p. 10115-10128, ISSN: 1420-3049, doi: 10.3390/molecules190710115.
206. Quattrocchi CC, Errante Y, Mallio CA, Carideo L, Scarciolla L, Santini D, Tonini G, Zobel BB. (2014). Inverse spatial distribution of brain metastases and white matter hyperintensities in advanced lung and non-lung cancer patients.. JOURNAL OF NEURO-ONCOLOGY, p. 321-330, ISSN: 0167-594X, doi: 10.1007/s11060-014-1554-7
207. Battisti S, Guida FM, Pagliara E, Tonini G, Zobel BB, Santini D (2014). Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view.. CLINICAL COLORECTAL CANCER, vol. 13(3), p. e13-e15, ISSN: 1533-0028, doi: 10.1016/j.clcc.2014.06.003

208. Vivaldi C, Fornaro L, Cereda S, Aprile G, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Brandi G, Vasile E. (2014). Second-line chemotherapy in advanced biliary cancer: the present now will later be past.. *ANNALS OF ONCOLOGY*, vol. 25(12), p. 2443-2444, ISSN: 0923-7534, doi: 10.1093/annonc/mdu379
209. Guida FM, Santoni M, Conti A, Burattini L, Savini A, Zeppola T, Caricato M, Cascinu S, Tonini G, Santini D (2014). Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*, vol. 92(3), p. 208-217, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2014.07.006
210. Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N. (2014). Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.. *PLOS ONE*, vol. 9(8), ISSN: 1932-6203, doi: 10.1371/journal.pone.0105268
211. Valeri S, Borzomati D, Nappo G, Perrone G, Santini D, Coppola R. (2014). Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.. *PANCREATOLOGY*, vol. 14(5), p. 425-430, ISSN: 1424-3903, doi: 10.1016/j.pan.2014.07.002.
212. D'Onofrio L, Tonini G, Santini D (2014). Clinical features of male breast cancer and multimodal treatment: a comment to retrospective survey analysis at Italian centers.. *TUMORI*, vol. 100(4), p. 169e-170e, ISSN: 0300-8916, doi: 10.1700/1636.17944.
213. Silvestris N, Vincenzi B, Brunetti AE, Loupakis F, Dell'Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V, Tonini G, Falcone A, Santini D (2014). Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.. *PHARMACOECONOMICS*, vol. 15(13), p. 1701-1715, ISSN: 1170-7690, doi: 10.2217/pgs.14.124.
214. Santini D, Zoccoli Alice, Gregorj Chiara, Di Cerbo Melania, Iuliani Michele, Pantano Francesco, Zamarchi Rita, Sergi Federico, Flammia Gerardo, Buscarini Maurizio, Rizzo Sergio, Cicero Giuseppe, Russo Antonio, Vincenzi Bruno, Avvisati Giuseppe, Tonini Giuseppe (2013). Zoledronic Acid Induces a Significant Decrease of Circulating Endothelial Cells and Circulating Endothelial Precursor Cells in the Early Prostate Cancer Neoadjuvant Setting. *ONCOLOGY*, vol. 85, p. 342-347, ISSN: 0030-2414, doi: 10.1159/000347226
215. Santini D, Lanzetta Gaetano, Dell'Aquila Emanuela, Vincenzi Bruno, Venditti Olga, Russano Marco, Papapietro Nicola, Denaro Vincenzo, Tonini Giuseppe, Ripamonti Carla (2013). 'Old' and 'new' drugs for the treatment of cancer pain. *EXPERT OPINION ON PHARMACOTHERAPY*, vol. 14, p. 425-433, ISSN: 1465-6566, doi: 10.1517/14656566.2013.774375
216. Rozzi Antonio, Santini D, Salerno Margherita, Bordin Francesca, Mancuso Andrea, Minniti Giuseppe, Nardoni Chiara, Corona Michela, Falbo Pina Tiziana, Recine Federica, Lanzetta Gaetano (2013). Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study. *MEDICAL ONCOLOGY*, vol. 30, ISSN: 1357-0560, doi: 10.1007/s12032-012-0407-5
217. Santini D, Frezza Anna Maria, Venditti Olga, Intagliata Salvatore, dell'Aquila Emanuela, Guida Francesco, Vincenzi Bruno, Tonini Giuseppe (2013). Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. *EXPERT OPINION ON THERAPEUTIC TARGETS*, vol. 17, p. 473-474, ISSN: 1472-8222, doi: 10.1517/14728222.2013.773269
218. Vincenzi Bruno, Zoccoli Alice, Schiavon Gaia, Iuliani Michele, Pantano Francesco, Dell'Aquila Emanuela, Ratta Raffaele, Muda Andrea Onetti, Perrone Giuseppe, Brunelli Chiara, Correale Pierpaolo, Riva Elisabetta, Russo Antonio, Loupakis Fotios, Falcone

- Alfredo, Santini D, Tonini Giuseppe (2013). Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. *EUROPEAN JOURNAL OF CANCER*, vol. 49, p. 1501-1508, ISSN: 0959-8049, doi: 10.1016/j.ejca.2012.11.014
219. Vincenzi Bruno, Frezza Anna Maria, Schiavon Gaia, Spoto Chiara, Addeo Raffaele, Catalano Vincenzo, Graziano Francesco, Santini D, Tonini Giuseppe (2013). Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. *SUPPORTIVE CARE IN CANCER*, vol. 21, p. 1313-1319, ISSN: 0941-4355, doi: 10.1007/s00520-012-1667-5
220. Santoni Matteo, De Tursi Michele, Felici Alessandra, Lo Re Giovanni, Ricotta Riccardo, Ruggeri Enzo Maria, Sabbatini Roberto, Santini D, Vaccaro Vanja, Milella Michele (2013). Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.. *EXPERT REVIEW OF ANTICANCER THERAPY*, vol. 13, p. 697-709, ISSN: 1473-7140, doi: 10.1586/era.13.52
221. Amadori Dino, Aglietta Massimo, Alessi Barbara, Gianni Lorenzo, Ibrahim Toni, Farina Gabriella, Gaion Fernando, Bertoldo Francesco, Santini D, Rondena Roberta, Bogani Paola, Ripamonti Carla I. (2013). Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. *LANCET ONCOLOGY*, vol. 14, p. 663-670, ISSN: 1470-2045, doi: 10.1016/S1470-2045(13)70174-8
222. Pantano Francesco, Guida Francesco Maria, Vivaldi Caterina, Vincenzi Bruno, Grande Enrique, Garrote Mercedes Rodriguez, Caraglia Michele, Silvestris Nicola, Vasile Enrico, Masi Gianluca, Falcone Alfredo, Tonini Giuseppe, Santini D (2013). Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. *CANCER BIOLOGY & THERAPY*, vol. 14, p. 467-468, ISSN: 1538-4047, doi: 10.4161/cbt.24346
223. Quattrocchi Carlo Cosimo, Errante Yuri, Mallio Carlo Augusto, Santini D, Tonini Giuseppe, Zobel Bruno Beomonte (2013). Brain metastatic volume and white matter lesions in advanced cancer patients. *JOURNAL OF NEURO-ONCOLOGY*, vol. 113, p. 451-458, ISSN: 0167-594X, doi: 10.1007/s11060-013-1137-z
224. Rolfo Christian, Russo Antonio, Santini D, Bronte Giuseppe, Peeters Marc (2013). Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting. *EXPERT OPINION ON THERAPEUTIC TARGETS*, vol. 17, p. 869-871, ISSN: 1472-8222, doi: 10.1517/14728222.2013.818135
225. Amadori Dino, Mercatali Laura, Nanni Oriana, Aglietta Massimo, Alessi Barbara, Gianni Lorenzo, Farina Gabriella, Gaion Fernando, Bertoldo Francesco, Santini D, Rondena Roberta, Bogani Paola, Ripamonti Carla Ida, Ibrahim Toni (2013). What can we learn from the ZOOM trial? Reply. *LANCET ONCOLOGY*, vol. 14, p. E388-E390, ISSN: 1470-2045
226. Pantano Francesco, Vincenzi Bruno, Santini D, Tonini Giuseppe (2013). Magnesium: are we better off without it?. *ANTI-CANCER DRUGS*, vol. 24, p. 879-880, ISSN: 0959-4973, doi: 10.1097/CAD.0b013e32836452d6 146 2013
227. Silvestris Nicola, Pantano Francesco, Ibrahim Toni, Gamucci Teresa, De Vita Fernando, Di Palma Teresa, Pedrazzoli Paolo, Barni Sandro, Bernardo Antonio, Febbraro Antonio, Satolli Maria Antonietta, Bertocchi Paola, Catalano Vincenzo, Giommoni Elisa, Comandone Alessandro, Maiello Evaristo, Riccardi Ferdinando, Ferrara Raimondo, Trogu Antonio, Berardi Rossana, Leo Silvana, Bertolini Alessandro, Angelini Francesco, Ciniere Saverio, Russo Antonio, Pisconti Salvatore, Brunetti Anna Elisabetta, Azzariti Amalia, Santini D (2013). Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. *PLOS ONE*, vol. 8, ISSN: 1932-6203, doi: 10.1371/journal.pone.0074402
228. Pantano Francesco, Berti Pierpaolo, Guida Francesco Maria, Perrone Giuseppe, Vincenzi Bruno, Amato Michelina Maria Carla, Righi Daniela, Dell'Aquila Emanuela,

- Graziano Francesco, Catalano Vincenzo, Caricato Marco, Rizzo Sergio, Muda Andrea Onetti, Russo Antonio, Tonini Giuseppe, Santini D (2013). The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. *JOURNAL OF CELLULAR AND MOLECULAR MEDICINE*, vol. 17, p. 1415-1421, ISSN: 1582-1838, doi: 10.1111/jcmm.12109
229. Suriano Francesca, Santini D, Perrone Giuseppe, Amato Michela, Vincenzi Bruno, Tonini Giuseppe, Muda Andrea Onetti, Boggia Sara, Buscarini Maurizio, Pantano Francesco (2013). Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 32, ISSN: 1756-9966, doi: 10.1186/1756-9966-32-87
230. Grimaldi Anna, Balestrieri Maria Luisa, D'Onofrio Nunzia, Di Domenico Gilda, Nocera Cosimo, Lamberti Monica, Tonini Giuseppe, Zoccoli Alice, Santini D, Caraglia Michele, Pantano Francesco (2013). The Synergistic Effect of Everolimus and Chloroquine on Endothelial Cell Number Reduction Is Paralleled by Increased Apoptosis and Reduced Autophagy Occurrence. *PLOS ONE*, vol. 8, ISSN: 1932-6203, doi: 10.1371/journal.pone.0079658
231. Tonini Giuseppe, Imperatori Marco, Vincenzi Bruno, Frezza Anna Maria, Santini D (2013). Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 32, ISSN: 1756-9966, doi: 10.1186/1756-9966-32-92
232. Santini D, Vincenzi Bruno, Venditti Olga, Dell'aquila Emanuela, Maria Frezza Anna, Silletta Marianna, Guida Francesco Maria, Grasso Rosario Francesco, Silvestris Nicola, Lanzetta Gaetano, Tonini Giuseppe (2013). Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?. *FUTURE ONCOLOGY*, vol. 9, p. 1809-1811, ISSN: 1744-8301, doi: 10.2217/fon.13.170
233. Santini D, Procopio Giuseppe, Porta Camillo, Ibrahim Toni, Barni Sandro, Mazzara Calogero, Fontana Andrea, Berruti Alfredo, Berardi Rossana, Vincenzi Bruno, Ortega Cinzia, Ottaviani Davide, Carteni Giacomo, Lanzetta Gaetano, Virzi Vladimir, Santoni Matteo, Silvestris Nicola, Satolli Maria Antonietta, Collova Elena, Russo Antonio, Badalamenti Giuseppe, Fedeli Stefano Luzi, Tanca Francesca Maria, Adamo Vincenzo, Maiello Evaristo, Sabbatini Roberto, Felici Alessandra, Cinieri Saverio, Tonini Giuseppe, Bracarda Sergio (2013). Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. *PLOS ONE*, vol. 8, ISSN: 1932-6203, doi: 10.1371/journal.pone.0083026
234. Santini D, Vincenzi B, Pantano F, Schiavon G, Tonini G. (2013). 'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer. . *ANNALS OF ONCOLOGY*, ISSN: 0923-7534, doi: 10.1093/annonc/mdt172
235. Amodeo V, Bazan V, Fanale D, Insalaco L, Caruso S, Cicero G, Bronte G, Rolfo C, Santini D, Russo A. (2013). Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?. *EXPERT OPINION ON THERAPEUTIC TARGETS*, vol. 17, p. 1249-1261, ISSN: 1472-8222, doi: 10.1517/14728222.2013.832206
236. Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunetti AE, Simone G, Nardulli P, Santini D, Aieta M, Delcuratolo S, Silvestris N. (2013). Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. . *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*, vol. 14, p. 19731-19762, ISSN: 1422-0067, doi: 10.3390/ijms141019731
237. Santoni M, Berardi R, Amantini C, Burattini L, Santini D, Santoni G, Cascinu S. (2013). Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. . *INTERNATIONAL JOURNAL OF CANCER*, ISSN: 0020-7136, doi: 10.1002/ijc.28503
238. Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S. (2013). Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-

- analysis of clinical trials. . INTERNATIONAL JOURNAL OF CANCER, ISSN: 0020-7136, doi: 10.1002/ijc.28544
239. Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, Rocco M, Di Gennaro E, Leone A, Luciano A, Arra C, Santini D, Caraglia M, Budillon A. (2013). Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. . CELL DEATH & DISEASE, vol. 4, ISSN: 2041-4889, doi: 10.1038/cddis.2013.406
  240. Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S. (2013). Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.. CANCER METASTASIS REVIEWS, ISSN: 0167-7659
  241. Vincenzi Bruno, Silletta Marianna, Schiavon Gaia, Frezza Anna Maria, Del Vescovo Raimondo, Zobel Bruno Beomonte, Santini D, Tos Angelo Paolo Dei, Tonini Giuseppe (2013). Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 22, p. 1-7, ISSN: 1354-3784, doi: 10.1517/13543784.2013.742886
  242. Morini Sergio, Perrone Giuseppe, Borzomati Domenico, Vincenzi Bruno, Rabitti Carla, Righi Daniela, Castri Federica, Manazza Andrea D., Santini D, Tonini Giuseppe, Coppola Roberto, Muda Andrea Onetti (2013). Carcinoma of the Ampulla of Vater Morphological and Immunophenotypical Classification Predicts Overall Survival. PANCREAS, vol. 42, p. 60-66, ISSN: 0885-3177, doi: 10.1097/MPA.0b013e318258fda8
  243. Vincenzi Bruno, Frezza Anna Maria, Schiavon Gaia, Santini D, Dileo Palma, Silletta Marianna, Delisi Delia, Bertoldo Francesco, Badalamenti Giuseppe, Baldi Giacomo Giulio, Zovato Stefania, Berardi Rossana, Tucci Marco, Silvestris Franco, Dei Tos Angelo Paolo, Tirabosco Roberto, Whelan Jeremy Simon, Tonini Giuseppe (2013). Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options.. CLINICAL SARCOMA RESEARCH, vol. 3, p. 6, ISSN: 2045-3329, doi: 10.1186/2045-3329-3-6
  244. Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, Loupakis F, Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M (2012). High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease. THE ONCOLOGIST, vol. 17, p. 823-829, ISSN: 1083-7159, doi: 10.1634/theoncologist.2012-0081
  245. Catalano V, Loupakis F, Graziano F, Bissoni R, Torresi U, Vincenzi B, Mari D, Giordani P, Alessandrini P, Salvatore L, Fornaro L, Santini D, Baldelli AM, Rossi D, Giustini L, Silva RR, Falcone A, D'Emidio S, Rocchi M, Luzi Fedeli S (2012). Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer III colon cancer. ANNALS OF ONCOLOGY, vol. 23, p. 135-141, ISSN: 0923-7534
  246. Catalano V, Vincenzi B, Giordani P, Graziano F, Santini D, Baldelli AM, Alessandrini P, Schiavon G, Rossi D, Casadei V, D'Emidio S, Luzi Fedeli S, Tonini G, Fiorentini G (2012). Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study. GASTRIC CANCER, ISSN: 1436-3291
  247. Santini D, Fratto ME, Aapro M (2012). Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumab. . RECENT RESULTS IN CANCER RESEARCH, vol. 192, p. 171-185, ISSN: 0080-0015
  248. Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G (2012). Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? . ANNALS OF ONCOLOGY, vol. 23, p. 2313-2318, ISSN: 0923-7534, doi: 10.1093/annonc/mdr623

249. Minoia C, Giannoccaro M, Iacobazzi A, Santini D, Silvestris N, Fioretti A, Oliva S, Guarini A (2012). Antineoplastic drug-induced bradyarrhythmias. *EXPERT OPINION ON DRUG SAFETY*, vol. 11, p. 739-751, ISSN: 1474-0338
250. Morini S, Perrone G, Borzomati D, Vincenzi B, Rabitti C, Righi D, Castri F, Manazza AD, Santini D, Tonini G, Coppola R, Onetti Muda A. (2012). Carcinoma of the Ampulla of Vater: Morphological and Immunophenotypical Classification Predicts Overall Survival. . *PANCREAS*, ISSN: 0885-3177
251. Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, Denaro V, Santini D, Tonini G (2012). Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. *JOURNAL OF HEMATOLOGY & ONCOLOGY*, vol. 5, p. 56, ISSN: 1756-8722
252. Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, Santini D, Caraglia M (2012). Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. *CANCER BIOLOGY & THERAPY*, vol. 13, p. 1491-1500, ISSN: 1538-4047, doi: 10.4161/cbt.22274
253. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G (2012). Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. *LANCET ONCOLOGY*, vol. 13, p. 1020-1024, ISSN: 1470-2045
254. Perrone G, Gaeta LM, Zagami M, Nasorri F, Coppola R, Borzomati D, Bartolozzi F, Altomare V, Trodella L, Tonini G, Santini D, Cavani A, Muda AO (2012). In Situ Identification of CD44+/CD24- Cancer Cells in Primary Human Breast Carcinomas. *PLOS ONE*, vol. 7, p. e43110, ISSN: 1932-6203
255. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, ESMO Guidelines Working Group. (2012). Management of cancer pain: ESMO Clinical Practice Guidelines.. *ANNALS OF ONCOLOGY*, vol. 23, p. 139-154, ISSN: 0923-7534, doi: 10.1093/annonc/mds233
256. Santini D, Addeo Raffaele, Vincenzi Bruno, Calvieri Alice, Montella Liliana, Silletta Marianna, Caraglia Michele, Vespasiani Umberto, Picardi Antonio, Del Prete Salvatore, Tonini Giuseppe (2012). Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. *EXPERT REVIEW OF ANTICANCER THERAPY*, vol. 12, p. 1283-1288, ISSN: 1473-7140, doi: 10.1586/ERA.12.102
257. Santini D, Bertoldo F, Dell'Aquila E, Cecchini I, Fregosi S, Bortolussi P, on behalf of the ZeTa study group (2012). The Italiancross-sectional survey of the management of bone metastasis: ZeTa study . *JOURNAL OF BONE ONCOLOGY*, vol. 1, p. 35-39, ISSN: 2212-1374
258. Quattrocchi CC, Dell'Aia P, Errante Y, Occhicone F, Longo D, Virzì V, Tonini G, Napoli N, Santini D, Zobel BB (2012). Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases . *JOURNAL OF BONE ONCOLOGY*, vol. 1, p. 24-29, ISSN: 2212-1374
259. Vincenzi B, Napolitano A, Santini D, Maiello E, Torri V, Tonini G (2012). Evidence-based guidelines: Improving AGREEment on consistence evaluation . *JOURNAL OF BONE ONCOLOGY*, vol. 1, p. 30-34, ISSN: 2212-1374
260. Insalaco L, Gaudio FD, Terrasi M, Amodeo V, Caruso S, Corsini LR, Fanale D, Margarese N, Santini D, Bazan V, Russo A (2012). Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. *JOURNAL OF CELLULAR AND MOLECULAR MEDICINE*, vol. 16, p. 2186-2195, ISSN: 1582-1838
261. Quattrocchi CC, Errante Y, Gaudio C, Mallio CA, Giona A, Santini D, Tonini G, Zobel BB (2012). Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients. *JOURNAL OF NEURO-ONCOLOGY*, vol. 110, p. 79-87, ISSN: 0167-594X
262. Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A,

- Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G (2012). Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. *ANNALS OF ONCOLOGY*, p. 2072-2077, ISSN: 0923-7534
263. Santini D, Virzi V, Vasile E, Vincenzi B, Catalano V, Graziano F, Masi G, Bronte G, Russo A, Falcone A, Tonini G (2012). A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients. *ONCOLOGY*, vol. 82, p. 75-82, ISSN: 0030-2414, doi: 10.1159/000329079
264. Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis F, Schiavon G, Frezza AM, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, Tonini G (2012). PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. *JOURNAL OF CELLULAR PHYSIOLOGY*, vol. 227, p. 927-933, ISSN: 0021-9541, doi: 10.1002/jcp.22801
265. Caraglia M, De Rosa G, Salzano G, Santini D, Lamberti M, Sperlongano P, Lombardi A, Abbruzzese A, Addeo R (2012). Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood-Brain-Barrier. *CURRENT CANCER DRUG TARGETS*, vol. 12, p. 186-196, ISSN: 1568-0096
266. Vincenzi B, Santini D, Schiavon G, Frezza AM, Silletta M, Crucitti P, Casali P, Dei Tos AP, Rossi S, Rizzo S, Badalamenti G, Tomasino RM, Russo A, Butrynski JE, Tonini G (2012). PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy. *JOURNAL OF CELLULAR PHYSIOLOGY*, vol. 227, p. 1657-1662, ISSN: 0021-9541, doi: 10.1002/jcp.22889
267. Zoccoli A, Iuliani M, Pantano F, Imperatori M, Intagliata S, Vincenzi B, Marchetti P, Papapietro N, Denaro V, Tonini G, Santini D (2012). Premetastatic niche: ready for new therapeutic interventions?. *EXPERT OPINION ON THERAPEUTIC TARGETS*, vol. 16, p. S119-S129, ISSN: 1472-8222, doi: 10.1517/14728222.2012.656092
268. Santini D, Vincenzi B, Pantano F, Tonini G, Bertoldo F (2011). Targeting bone metastases starting from the preneoplastic niche: home sweet home. *BREAST CANCER RESEARCH*, vol. 13, ISSN: 1465-542X, doi: 10.1186/bcr2911 189 2011
269. Tonini G, Fratto ME, Imperatori M, Pantano F, Vincenzi B, Santini D (2011). Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. *EXPERT REVIEW OF ANTICANCER THERAPY*, vol. 11, p. 921-930, ISSN: 1473-7140, doi: 10.1586/ERA.11.63
270. Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli MA, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio MR, Marra M, Caraglia M, Tonini G (2011). Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. *ONCOLOGY REPORTS*, vol. 25, p. 1545-1548, ISSN: 1021-335X, doi: 10.3892/or.2011.1235
271. Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A (2011). Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*, vol. 78, p. 243-251, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2010.06.003
272. Ruzzo A, Canestrari E, Galluccio N, Santini D, Vincenzi B, Tonini G, Magnani M, Graziano F (2011). Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. *ANNALS OF ONCOLOGY*, vol. 22, p. 234-U274, ISSN: 0923-7534, doi: 10.1093/annonc/mdq472
273. Santini D, Galluzzo S, Gaeta L, Zoccoli A, Riva E, Ruzzo A, Vincenzi B, Graziano F, Loupakis F, Falcone A, Muda AO, Tonini G (2011). Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis?. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 29, p. E206-E207, ISSN: 0732-183X, doi: 10.1200/JCO.2010.32.7700



274. Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Muda AO, Denaro V, Tonini G (2011). Expression Pattern of Receptor Activator of NF kappa B (RANK) in a Series of Primary Solid Tumors and Related Bone Metastases. *JOURNAL OF CELLULAR PHYSIOLOGY*, vol. 226, p. 780-784, ISSN: 0021-9541, doi: 10.1002/jcp.22402
275. Tonini G, Vincenzi B, Santini D (2011). Bisphosphonate anticancer activity. *EXPERT OPINION ON PHARMACOTHERAPY*, vol. 12, p. 681-683, ISSN: 1465-6566, doi: 10.1517/14656566.2011.543279
276. Catalano V, Mellone P, d'Avino A, Shridhar V, Staccioli MP, Graziano F, Giordani P, Rossi D, Baldelli AM, Alessandrini P, Santini D, Lorenzon L, Testa E, D'Emidio S, De Nictolis M, Muretto P, Fedeli SL, Baldi A (2011). HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. *HISTOPATHOLOGY*, vol. 58, p. 669-678, ISSN: 0309-0167, doi: 10.1111/j.1365-2559.2011.03818.x
277. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G (2011). Receptor Activator of NF-kappa B (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. *PLOS ONE*, vol. 6, ISSN: 1932-6203, doi: 10.1371/journal.pone.0019234
278. Vincenzi B, Santini D, Frezza AM, Berti P, Vespasiani U, Picardi A, Tonini G (2011). The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. *EXPERT OPINION ON DRUG SAFETY*, vol. 10, p. 345-349, ISSN: 1474-0338, doi: 10.1517/14740338.2011.562888
279. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F (2011). Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. *BMC CANCER*, vol. 11, ISSN: 1471-2407, doi: 10.1186/1471-2407-11-247
280. Tommasi S, Pinto R, Petriella D, Pilato B, Lacalamita R, Santini D, Zito F, Colucci G, Paradiso A, Silvestris N (2011). Oncosuppressor Methylation: A Possible Key Role in Colon Metastatic Progression. *JOURNAL OF CELLULAR PHYSIOLOGY*, vol. 226, p. 1934-1939, ISSN: 0021-9541, doi: 10.1002/jcp.22524
281. Pantano F, Zoccoli A, Iuliani M, Lanzetta G, Vincenzi B, Tonini G, Santini D (2011). New targets, new drugs for metastatic bone pain: a new philosophy. *EXPERT OPINION ON EMERGING DRUGS*, vol. 16, p. 403-405, ISSN: 1472-8214, doi: 10.1517/14728214.2011.588600
282. Vincenzi B, Napolitano A, D'Onofrio L, Frezza AM, Silletta M, Venditti O, Santini D, Tonini G (2011). Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. *EXPERT OPINION ON INVESTIGATIONAL DRUGS*, vol. 20, p. 1685-1705, ISSN: 1354-3784, doi: 10.1517/13543784.2011.628984
283. Caraglia M, Santini D, Bronte G, Rizzo S, Sortino G, Rini GB, Di Fede G, Russo A (2011). Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules. *CURRENT DRUG METABOLISM*, vol. 12, p. 944-955, ISSN: 1389-2002
284. Vitale G, Dicitore A, Sciortino G, Abbruzzese A, Persani L, Santini D (2011). Role of GPR30 in testicular germ cell tumors: a potential new anticancer target. *CANCER BIOLOGY & THERAPY*, vol. 11, p. 773-775, ISSN: 1538-4047
285. Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G (2011). Early magnesium modifications as a surrogate marker of efficacy of cetuximab-

- based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. *ANNALS OF ONCOLOGY*, vol. 22, p. 1141-1146, ISSN: 0923-7534
286. Fratto ME, Santini D, Vincenzi B, Silvestris N, Azzariti A, Tommasi S, Zoccoli A, Galluzzo S, Maiello E, Colucci G, Tonini G (2011). Targeting EGFR in bilio-pancreatic and liver carcinoma. *FRONTIERS IN BIOSCIENCE*, vol. 3, p. 16-22, ISSN: 1945-0516
  287. Fratto ME, Imperatori M, Vincenzi B, Tomao F, Santini D, Tonini G (2011). New perspectives: role of Sunitinib in breast cancer. *LA CLINICA TERAPEUTICA*, vol. 162, p. 251-257, ISSN: 0009-9074
  288. Santini D, Pantano F, Vincenzi B, Tonini G (2011). Emerging Therapeutic Targets in Osteoncolgy. *ONCOLOGY*, vol. 80, p. 223-224, ISSN: 0030-2414, doi: 10.1159/000327573
  289. Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G (2011). Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC). *CURRENT CANCER DRUG TARGETS*, vol. 11, p. 123-129, ISSN: 1568-0096, doi: 10.2174/156800911793743600
  290. Lombardi L, Morelli F, Cinieri S, Santini D, Silvestris N, Fazio N, Orlando L, Tonini G, Colucci G, Maiello E (2010). Adjuvant colon cancer chemotherapy: where we are and where we'll go. *CANCER TREATMENT REVIEWS*, vol. 36, p. S34-S41, ISSN: 0305-7372, doi: 10.1016/S0305-7372(10)70018-9
  291. Vincenzi B, Frezza AM, Santini D, Tonini G (2010). Target therapy in gastrointestinal tract sarcoma: What is new? . *WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY*, vol. 2, p. 1-4, ISSN: 1948-5204
  292. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G (2010). Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. *THE ONCOLOGIST*, vol. 15, p. 85-92, ISSN: 1083-7159, doi: 10.1634/theoncologist.2009-0143
  293. Perrone G, Morini S, Santini D, Rabitti C, Vincenzi B, Alloni R, Antinori A, Magistrelli P, Lai R, Cass C, Mackey JR, Coppola R, Tonini G, Muda AO (2010). Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. *EUROPEAN JOURNAL OF HISTOCHEMISTRY*, vol. 54, p. 166-169, ISSN: 1121-760X, doi: 10.4081/ejh.2010.e38
  294. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A (2010). Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. *CANCER TREATMENT REVIEWS*, vol. 36, p. S21-S29, ISSN: 0305-7372, doi: 10.1016/S0305-7372(10)70016-5
  295. Tonini G, Intagliata S, Cagli B, Segreto F, Perrone G, Muda AO, Santini D, Persichetti P (2010). Recurrent Scrotal Hemangiomas During Treatment With Sunitinib. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 28, p. E737-E738, ISSN: 0732-183X, doi: 10.1200/JCO.2010.30.4865
  296. Vincenzi B, Tonini G, Santini D (2010). Aprepitant for erlotinib-induced pruritus.. *NEW ENGLAND JOURNAL OF MEDICINE*, ISSN: 0028-4793
  297. Santini D, Galluzzo S, Vincenzi B, Zoccoli A, Ferraro E, Lippi C, Altomare V, Tonini G, Bertoldo F (2010). Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. *ANNALS OF ONCOLOGY*, vol. 21, p. 185-186, ISSN: 0923-7534, doi: 10.1093/annonc/mdp497
  298. Santini D, Virzi V, Fratto ME, Bertoldo F, Sabbatini R, Berardi R, Calipari N, Ottaviani D, Ibrahim T (2010). Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting. *CURRENT CANCER DRUG TARGETS*, vol. 10, p. 46-54, ISSN: 1568-0096

299. Pantano F, Santini D, Guida F, Vincenzi B, Tonini G (2010). Potential role of everolimus in inducing cholestasis. *ANNALS OF ONCOLOGY*, vol. 21, ISSN: 0923-7534, doi: 10.1093/annonc/mdp558
300. Tonini G, Fratto ME, Vincenzi B, Santini D (2010). Chemotherapy in biliary tract cancer. *EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES*, vol. 14, p. 371-374, ISSN: 1128-3602
301. Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, Graziano F (2010). Prognostic Role of Human Equilibrative Transporter 1 (hENT1) in Patients With Resected Gastric Cancer. *JOURNAL OF CELLULAR PHYSIOLOGY*, vol. 223, p. 384-388, ISSN: 0021-9541, doi: 10.1002/jcp.22045
302. Vincenzi B, Napolitano A, Frezza AM, Schiavon G, Santini D, Tonini G (2010). Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. *PHARMACOGENOMICS*, vol. 11, p. 865-878, ISSN: 1462-2416, doi: 10.2217/PGS.10.69
303. Vincenzi B, Frezza AM, Santini D, Tonini G (2010). New therapies in soft tissue sarcoma. *EXPERT OPINION ON EMERGING DRUGS*, vol. 15, p. 237-248, ISSN: 1472-8214, doi: 10.1517/14728211003592108
304. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A (2010). Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. *ENDOCRINE-RELATED CANCER*, vol. 17, p. 445-453, ISSN: 1351-0088, doi: 10.1677/ERC-09-0281
305. Santini D, Spoto C, Loupakis F, Vincenzi B, Silvestris N, Cremolini C, Canestrari E, Graziano F, Galluccio N, Salvatore L, Caraglia M, Zito FA, Colucci G, Falcone A, Tonini G, Ruzzo A (2010). High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. *ANNALS OF ONCOLOGY*, vol. 21, p. 1565, ISSN: 0923-7534, doi: 10.1093/annonc/mdq318
306. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilias G, Kalogeris KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *LANCET ONCOLOGY*, vol. 11, p. 753-762, ISSN: 1470-2045, doi: 10.1016/S1470-2045(10)70130-3
307. Vincenzi B, Fratto ME, Santini D, Tonini G (2010). Aprepitant against pruritus in patients with solid tumours. *SUPPORTIVE CARE IN CANCER*, vol. 18, p. 1229-1230, ISSN: 0941-4355, doi: 10.1007/s00520-010-0895-9
308. Graziano F, Ruzzo A, Canestrari E, Catalano V, Santini D, Galluccio N, Loupakis F, Alessandrini P, Spada D, Ficarelli R, Bissoni R, D'Emidio S, Vincenzi B, Angeletti S, Salvatore L, Cremolini C, Tonini G, Falcone A (2010). Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. *PHARMACOGENOMICS*, vol. 11, p. 1247-1256, ISSN: 1462-2416, doi: 10.2217/PGS.10.92
309. Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G (2010). PML Down-Regulation in Soft Tissue Sarcomas. *JOURNAL OF CELLULAR PHYSIOLOGY*, vol. 224, p. 644-648, ISSN: 0021-9541, doi: 10.1002/jcp.22161
310. Fratto ME, Imperatori M, Vincenzi B, Tomao F, Santini D, Tonini G (2010). New perspectives: role of Sunitinib in Breast Cancer. *LA CLINICA TERAPEUTICA*, vol. 161, p. 475-482, ISSN: 0009-9074

311. Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M (2010). Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. *PHARMACOGENOMICS JOURNAL*, vol. 10, p. 458-464, ISSN: 1470-269X, doi: 10.1038/tpj.2010.9
312. Santini D, Fratto ME, Spoto C, Russo A, Galluzzo S, Zoccoli A, Vincenzi B, Tonini G (2010). Cetuximab in small bowel adenocarcinoma: a new friend?. *BRITISH JOURNAL OF CANCER*, vol. 103, p. 1305, ISSN: 0007-0920, doi: 10.1038/sj.bjc.6605898
313. Silvestris N, Maiello E, De Vita F, Cinieri S, Santini D, Russo A, Tommasi S, Azzariti A, Numico G, Pisconti S, Petriella D, Lorusso V, Millaku A, Colucci G (2010). Update on capecitabine alone and in combination regimens in colorectal cancer patients. *CANCER TREATMENT REVIEWS*, vol. 36, p. S46-S55, ISSN: 0305-7372, doi: 10.1016/S0305-7372(10)70020-7
314. Santini D, Galluzzo S, Zoccoli A, Pantano F, Fratto ME, Vincenzi B, Lombardi L, Gucciardino C, Silvestris N, Riva E, Rizzo S, Russo A, Maiello E, Colucci G, Tonini G (2010). New molecular targets in bone metastases. *CANCER TREATMENT REVIEWS*, vol. 36, p. S6-S10, ISSN: 0305-7372, doi: 10.1016/S0305-7372(10)70013-X
315. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A (2010). Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. *CANCER TREATMENT REVIEWS*, vol. 36, p. S56-S61, ISSN: 0305-7372, doi: 10.1016/S0305-7372(10)70021-9
316. Di Martino A, Vincenzi B, Denaro L, Barnaba SA, Papalia R, Santini D, Tonini G, Denaro V (2009). 'Internal bracing' surgery in the management of solid tumor metastases of the thoracic and lumbar spine. *ONCOLOGY REPORTS*, vol. 21, p. 431-435, ISSN: 1021-335X, doi: 10.3892/or\_00000241
317. Angeletti S, Galluzzo S, Santini D, Ruzzo A, Vincenzi B, Ferraro E, Spoto C, Lorino G, Graziano N, Calvieri A, Magnani M, Graziano F, Pantano F, Tonini G, Dicuonzo G (2009). NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population. *HUMAN IMMUNOLOGY*, vol. 70, p. 729-732, ISSN: 0198-8859, doi: 10.1016/j.humimm.2009.04.026
318. Pantano F, Silletta M, Iovieno A, Vincenzi B, Santini D, Galluzzo S, Bonini S, Tonini G (2009). Stevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitumumab. *INTERNATIONAL JOURNAL OF COLORECTAL DISEASE*, vol. 24, p. 1247-1248, ISSN: 0179-1958, doi: 10.1007/s00384-009-0676-4
319. Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R, Tonini G (2009). Bevacizumab in Association With de Gramont 5-Fluorouracil/Folinic Acid in Patients With Oxaliplatin-, Irinotecan-, and Cetuximab-Refractory Colorectal Cancer A Single-Center Phase 2 Trial. *CANCER*, vol. 115, p. 4849-4856, ISSN: 0008-543X, doi: 10.1002/cncr.24540
320. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Addeo SR, Abbruzzese A, Budillon A, Caraglia M (2009). Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. *INTERNATIONAL JOURNAL OF CANCER*, vol. 125, p. 2004-2013, ISSN: 0020-7136, doi: 10.1002/ijc.24648
321. Santini D, Fratto ME, Vincenzi B, Napoli N, Galluzzo S, Tantardini M, Abbruzzese A, Caraglia M, Tonini G (2009). Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases. *CURRENT CANCER DRUG TARGETS*, vol. 9, p. 834-842, ISSN: 1568-0096
322. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, Tagliaferri P, Santini D, Caraglia M (2009). Cutting the Limits of Aminobisphosphonates: New Strategies

- for the Potentiation of their Anti-Tumour Effects. *CURRENT CANCER DRUG TARGETS*, vol. 9, p. 791-800, ISSN: 1568-0096
323. Tonini G, Virzi V, Fratto ME, Vincenzi B, Santini D (2009). Targeted therapy in biliary tract cancer: 2009 update. *FUTURE ONCOLOGY*, vol. 5, p. 1675-1684, ISSN: 1479-6694, doi: 10.2217/FON.09.130
324. Maltese P, Canestrari E, Ruzzo A, Graziano F, Falcone A, Loupakis F, Tonini G, Santini D, Magnani M (2009). VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. *INTERNATIONAL JOURNAL OF COLORECTAL DISEASE*, vol. 24, p. 165-170, ISSN: 0179-1958, doi: 10.1007/s00384-008-0586-x
325. Vitale G, Abbruzzese A, Tonini G, Santini D (2009). Chemo-immunotherapy A new option for non-small cell lung cancer. *CANCER BIOLOGY & THERAPY*, vol. 8, p. 503-504, ISSN: 1538-4047, doi: 10.4161/cbt.8.6.7770
326. Bertoldo F, Tonini G, Vincenzi B, Santini D (2009). Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer. *NATURE REVIEWS. CLINICAL ONCOLOGY*, vol. 6, p. 191-192, ISSN: 1759-4774, doi: 10.1038/nrclinonc.2009.24
327. Silvestris N, Tommasi S, Santini D, Russo A, Simone G, Petriella D, Maiello E, Tonini G, Colucci G (2009). KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. *EXPERT OPINION ON BIOLOGICAL THERAPY*, vol. 9, p. 565-577, ISSN: 1471-2598, doi: 10.1517/14712590902870394
328. Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D, Vincenzi B, Gebbia N, Carreca I (2009). Gemcitabine-based Doublets Versus Single-agent Therapy for Elderly Patients With Advanced Nonsmall Cell Lung Cancer A Literature-based Meta-analysis. *CANCER*, vol. 115, p. 1924-1931, ISSN: 0008-543X, doi: 10.1002/cncr.24207
329. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A (2009). PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 27, p. 2622-2629, ISSN: 0732-183X, doi: 10.1200/JCO.2008.20.2796
330. Pantano F, Baldi A, Santini D, Vincenzi B, Borzomati D, Vecchio FM, Castri F, Antinori A, Caraglia M, Magistrelli P, Coppola R, Tonini G (2009). MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients. *CANCER BIOLOGY & THERAPY*, vol. 8, p. 996-999, ISSN: 1538-4047, doi: 10.4161/cbt.8.11.8537
331. Tonini G, Fratto ME, Vincenzi B, Santini D (2009). Classification of biliary tract cancer (BTC): evaluation of all entities. *ANNALS OF ONCOLOGY*, vol. 20, p. 1148-1149, ISSN: 0923-7534, doi: 10.1093/annonc/mdp275
332. Vincenzi B, Santini D, Loupakis F, Addeo R, Llimpe FLR, Baldi GG, Di Fabio F, Del Prete S, Pinto C, Falcone A, Tonini G (2009). Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. *EXPERT OPINION ON BIOLOGICAL THERAPY*, vol. 9, p. 945-949, ISSN: 1471-2598, doi: 10.1517/14712590903081694
333. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F (2009). KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. *BRITISH JOURNAL OF CANCER*, vol. 101, p. 715-721, ISSN: 0007-0920, doi: 10.1038/sj.bjc.6605177
334. Caraglia M, Santini D (2009). Target therapy of bone metastases and tumours. *CURRENT CANCER DRUG TARGETS*, vol. 9, p. 789-790, ISSN: 1568-0096
335. Floriani I, Santini D, Torri V, Cremolini C, Falcone A, Loupakis F (2009). Do we need biopsies of metastases for colorectal cancer patients? . *BRITISH JOURNAL OF CANCER*, vol. 101, p. 374-375, ISSN: 0007-0920

336. Tonini G, Calvieri A, Vincenzi B, Santini D (2009). First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. *ONCOTARGETS AND THERAPY*, vol. 2, p. 73-82, ISSN: 1178-6930
337. Silvestris N, Tommasi S, Petriella D, Santini D, Fistola E, Russo A, Numico G, Tonini G, Maiello E, Colucci G (2009). The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. *ONCOLOGY*, vol. 77, p. 69-74, ISSN: 0030-2414, doi: 10.1159/000258498
338. Spugnini EP, Vincenzi B, Caruso G, Baldi A, Citro G, Santini D, Tonini G (2009). Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. *JOURNAL OF SMALL ANIMAL PRACTICE*, vol. 50, p. 44-46, ISSN: 0022-4510, doi: 10.1111/j.1748-5827.2008.00635.x
339. Santini D, Fratto ME, Galluzzo S, Vincenzi B, Tonini G (2009). Are bisphosphonates the suitable anticancer drugs for the elderly?. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*, vol. 69, p. 83-94, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2008.07.008
340. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, Turchi F, Piacentini P, Rocci L, Manavalan JS, Tonini G, Poccia F (2009). In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients. *CANCER IMMUNOLOGY, IMMUNOTHERAPY*, vol. 58, p. 31-38, ISSN: 0340-7004, doi: 10.1007/s00262-008-0521-6
341. Vincenzi B, Santini D, Perrone G, Russo A, Adamo V, Rizzo S, Castri F, Antinori A, Alloni R, Crucitti PF, Morini S, Rabitti C, Vecchio FM, Magistrelli P, Coppola R, Tonini G (2009). Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients. *ANNALS OF ONCOLOGY*, vol. 20, p. 78-83, ISSN: 0923-7534, doi: 10.1093/annonc/mdn558
342. Graziano F, Ruzzo A, Canestrari E, Loupakis F, Santini D, Rulli E, Humar B, Galluccio N, Bissoni R, Floriani I, Maltese P, Falcone A, Tonini G, Catalano V, Fontana A, Giustini L, Masi G, Vincenzi B, Alessandrini P, Magnani M (2009). Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. *PHARMACOGENOMICS JOURNAL*, vol. 9, p. 78-84, ISSN: 1470-269X, doi: 10.1038/tj.2008.16
343. Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, Guarrasi R, Rossi E, Cennamo G, Tonini G, Capasso E, Santini D, Caraglia M, Del Prete S (2008). Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. *SUPPORTIVE CARE IN CANCER*, vol. 16, p. 209-214, ISSN: 0941-4355, doi: 10.1007/s00520-007-0315-y
344. Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandrini P, Testa E, Tonini G, Catalano G (2008). Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?. *BRITISH JOURNAL OF CANCER*, vol. 99, p. 1402-1407, ISSN: 0007-0920, doi: 10.1038/sj.bjc.6604732
345. Vincenzi B, Patti G, Galluzzo S, Pantano F, Venditti O, Santini D, Ruzzo A, Schiavon G, Caraglia M, Marra M, Graziano F, Tonini G (2008). Interleukin 1ss-511T gene (IL1ss) polymorphism is correlated with gastric cancer in the Caucasian population: Results from a meta-analysis. *ONCOLOGY REPORTS*, vol. 20, p. 1213-1220, ISSN: 1021-335X, doi: 10.3892/or\_00000132
346. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G (2008). The biological properties of cetuximab. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*, vol. 68, p. 93-106, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2008.07.006
347. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, Calvieri A, Pizzagalli F, Graziano N, Ferraro E, Lorino G, Altomare A, Magnani M, Graziano F, Tonini G (2008). Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. *CLINICAL AND EXPERIMENTAL IMMUNOLOGY*, vol. 154, p. 360-364, ISSN: 0009-9104, doi: 10.1111/j.1365-2249.2008.03776.x

348. GRAZIANO F, RUZZO A, LOUPAKIS F, CANESTRARI E, SANTINI D, CATALANO V, BISONNI R, TORRESI U, FLORIANI I, SCHIAVON G, ANDREONI F, MALTESE P, RULLI E, HUMAR B, FALCONE A, GIUSTINI L, TONINI G, FONTANA A, MASI G, MAGNANI M (2008). Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 26(9), p. 1427-1434, ISSN: 0732-183X
349. PERRONE G, RUFFINI PA, CATALANO V, SPINO C, SANTINI D, MURETTO P, SPOTO C, ZINGARETTI C, SISTI V, ALESSANDRONI P, GIORDANI P, CICETTI A, D'EMIDIO S, MORINI S, RUZZO A, MAGNANI M, TONINI G, RABITTI C, GRAZIANO F (2008). Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. *EUROPEAN JOURNAL OF CANCER*, vol. 44(13), p. 1875-1882, ISSN: 0959-8049
350. SANTINI D, PERRONE G, VINCENZI B, LAI R, CASS C, ALLONI R, RABITTI C, ANTINORI A, VECCHIO F, MORINI S, MAGISTRELLI P, COPPOLA R, MACKAY JR, TONINI G (2008). Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. *ANNALS OF ONCOLOGY*, ISSN: 0923-7534
351. Tonini G, Schiavon G, Fratto ME, Vincenzi B, Santini D (2008). Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directions. *EXPERT OPINION ON BIOLOGICAL THERAPY*, vol. 8, p. 221-234, ISSN: 1471-2598, doi: 10.1517/14712598.8.2.221
352. Casale M, Rinaldi V, Quattrocchi C, Bressi F, Vincenzi B, Santini D, Tonini G, Salvinelli F (2008). Atypical chronic head and neck pain: don't forget Eagle's syndrome. *EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES*, vol. 12, p. 131-133, ISSN: 1128-3602
353. Santini D, Vincenzi B, Tonini G (2008). Updated follow-up of patients treated with bortezomib for relapsed multiple myeloma. *NATURE CLINICAL PRACTICE ONCOLOGY*, vol. 5, p. 304-305, ISSN: 1743-4254, doi: 10.1038/ncponc1127
354. Adamo V, Caristi N, Sacca MM, Ferraro G, Arcana C, Maisano R, Santini D, Tonini G (2008). Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. *EXPERT OPINION ON PHARMACOTHERAPY*, vol. 9, p. 1351-1361, ISSN: 1465-6566, doi: 10.1517/14656560802098253
355. Vincenzi B, Santini D, Tonini G (2008). Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesium. *EXPERT OPINION ON PHARMACOTHERAPY*, vol. 9, p. 1267-1269, ISSN: 1465-6566, doi: 10.1517/14656560802048985
356. Caccamo N, Meraviglia S, Scarpa F, La Mendola C, Santini D, Bonanno CT, Misiano G, Dieli F, Salerno A (2008). Aminobisphosphonate-activated gamma delta T cells in immunotherapy of cancer: doubts no more. *EXPERT OPINION ON BIOLOGICAL THERAPY*, vol. 8, p. 875-883, ISSN: 1471-2598, doi: 10.1517/14712590802102989
357. Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfaro F, Silletta M, Battistoni F, Rocci L, Zobel BB, Adamo V, Dicuonzo G, Tonini G (2008). Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. *CLINICAL CANCER RESEARCH*, vol. 14, p. 4219-4224, ISSN: 1078-0432, doi: 10.1158/1078-0432.CCR-08-0077
358. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E, Menichetti ET, Magnani M (2008). Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. *PHARMACOGENOMICS JOURNAL*, vol. 8, p. 278-288, ISSN: 1470-269X, doi: 10.1038/sj.tpj.6500463
359. Vincenzi B, Schiavon G, Pantano F, Santini D, Tonini G (2008). Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. *NATURE*

- CLINICAL PRACTICE ONCOLOGY, vol. 5, p. 455-465, ISSN: 1743-4254, doi: 10.1038/ncponc1137
360. Graziano F, Ruzzo A, Loupakis F, Santini D, Catalano V, Canestrari E, Maltese P, Bissoni R, Fornaro L, Baldi G, Masi G, Falcone A, Tonini G, Giordani P, Alessandrini P, Giustini L, Vincenzi B, Magnani M (2008). Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. BRITISH JOURNAL OF CANCER, vol. 99, p. 716-721, ISSN: 0007-0920, doi: 10.1038/sj.bjc.6604555
361. Zardi EM, Di Matteo F, Santini D, Uwechie V, Crucitti P, Carassiti M, Picardi A, Perrella E, Caricato M, Tonini G, Coppola R, Afeltra A (2008). Pancreatitis after percutaneous ethanol injection into HCC: a minireview of the literature. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 27, ISSN: 1756-9966, doi: 10.1186/1756-9966-27-28
362. Santini D, Pantano F, Vincenzi B, Loupakis F, Caraglia M, Falcone A, Tonini G (2008). Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, vol. 6, p. 86-90, ISSN: 1359-6349, doi: 10.1016/j.ejcsup.2008.06.008
363. Marra M, Santini D, Tonini G, Meo G, Zappavigna S, Facchini G, Morabito A, Abbruzzese A, Carteni G, Budillon A, Caraglia M (2008). Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, vol. 6, p. 79-85, ISSN: 1359-6349, doi: 10.1016/j.ejcsup.2008.06.023
364. Borzomati D, Valeri S, Grasso F, Rabitti C, Vitolo D, Santini D, Vincenzi B, Garberini A, La Vaccara V, Coppola R (2008). Pancreatic intraductal papillary mucinous neoplasms: a paradigmatic case. A case report and review of the literature. CHIRURGIA ITALIANA, vol. 60, p. 567-572, ISSN: 0009-4773
365. Loupakis F, Vasile E, Santini D, Masi G, Falcone A, Graziano F (2008). EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. PHARMACOGENOMICS, vol. 9, p. 55-69, ISSN: 1462-2416, doi: 10.2217/14622416.9.1.55
366. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L, Russo A, Perrone G, Tommasino MR, Magnani M, Falcone A, Tonini G, Ruzzo A (2008). High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. THE ONCOLOGIST, vol. 13, p. 1270-1275, ISSN: 1083-7159, doi: 10.1634/theoncologist.2008-0181
367. Giorgio CG, Pappalardo A, Russo A, Santini D, Di Rosa C, Di Salvo C, Castorina S, Marletta F, Bellissima G, Palermo N, Scuderi C, Bordonaro R (2007). A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. ANTI-CANCER DRUGS, vol. 18, p. 713-719, ISSN: 0959-4973, doi: 10.1097/CAD.0b013e328082558a
368. Vincenzi B, Santini D, Tonini G (2007). Cetuximab: from biology to the care of colorectal cancer patients. FUTURE ONCOLOGY, vol. 3, p. 497-499, ISSN: 1082-331X
369. Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL (2007). The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 26, p. 307-312, ISSN: 0392-9078
370. Tonini G, Schiavon G, Silletta M, Vincenzi B, Santini D (2007). Antiangiogenic properties of metronomic chemotherapy in breast cancer. FUTURE ONCOLOGY, vol. 3, p. 183-190, ISSN: 1082-331X
371. Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A (2007). The role of Aurora-A inhibitors in cancer therapy. ANNALS OF ONCOLOGY, vol. Suppl 6, p. vi47-vi52, ISSN: 0923-7534



372. Ruzzo A, Canestrari E, Maltese P, Pizzagalli F, Graziano F, Santini D, Catalano V, Ficarelli R, Mari D, Bissoni R, Giordani P, Giustini L, Lippe P, Silva R, Mattioli R, Torresi U, Latini L, Magnani M (2007). Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. *CLINICAL CHEMISTRY AND LABORATORY MEDICINE*, vol. 45, p. 822-828, ISSN: 1434-6621, doi: 10.1515/CCLM.2007.143
373. Vincenzi B, Santini D, Frezza AM, Rocci L, Tonini G (2007). Docetaxel induced pericardial effusion. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 26, p. 417-420, ISSN: 0392-9078
374. Santini D, Baldi A, Vincenzi B, Mellone P, Campioni M, Antinori A, Borzomati D, Coppola R, Magistrelli P, Tonini G (2007). Mucin 2 (MUC2) and mucin 5 (MUC5) expression is not associated with prognosis in patients with radically resected ampullary carcinoma. *JOURNAL OF CLINICAL PATHOLOGY*, vol. 60, p. 1069-1070, ISSN: 0021-9746, doi: 10.1136/jcp.2005.035832
375. Spugnini EP, Vincenzi B, Citro G, Santini D, Dotsinsky I, Mudrov N, Montesarchio V, Laieta MT, Esposito V, Baldi A (2007). Adjuvant electrochemotherapy for the treatment of incompletely excised spontaneous canine sarcomas. *IN VIVO*, vol. 21, p. 819-822, ISSN: 0258-851X
376. Vincenzi B, Calvieri A, Santini D, Altomare V, Tonini G (2007). Occasional FDG-PET recognition of in situ breast cancer. *ANNALS OF ONCOLOGY*, vol. 18, p. 1584-1585, ISSN: 0923-7534, doi: 10.1093/annonc/mdm418
377. Abbate A, Morales C, De Falco M, Fedele V, Zoccai GGLB, Santini D, Palleiro J, Vasaturo F, Scarpa S, Liuzzo G, Severino A, Baldi F, Crea F, Biasucci LM, Vetrovec GW, Gelpi RJ, Baldi A (2007). Ischemia and apoptosis in an animal model of permanent infarct-related artery occlusion. *INTERNATIONAL JOURNAL OF CARDIOLOGY*, vol. 121, p. 109-111, ISSN: 0167-5273, doi: 10.1016/j.ijcard.2006.08.077
378. Quattrocchi CC, Piciucchi S, Sammarra M, Santini D, Vincenzi B, Tonini G, Grasso RF, Zobel BB (2007). Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. *LA RADIOLOGIA MEDICA*, vol. 112, p. 1049-1059, ISSN: 0033-8362, doi: 10.1007/s11547-007-0205-x
379. Santini D, Vincenzi B, Tonini G (2007). Zoledronic acid and angiogenesis - Response. *CLINICAL CANCER RESEARCH*, vol. 13, p. 6850-6851, ISSN: 1078-0432, doi: 10.1158/1078-0432.CCR-07-4408
380. Quattrocchi CC, Santini D, Dell'Aia P, Piciucchi S, Leoncini E, Vincenzi B, Grasso RF, Tonini G, Zobel BB (2007). A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid. *SKELETAL RADIOLOGY*, vol. 36, p. 1121-1127, ISSN: 0364-2348, doi: 10.1007/s00256-007-0388-1
381. Bertoldo F, Santini D, Lo Cascio V (2007). Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. *NATURE CLINICAL PRACTICE ONCOLOGY*, vol. 4, p. 711-721, ISSN: 1743-4254, doi: 10.1038/ncponcl000
382. Russo A, Fratto ME, Bazan V, Schiro V, Agnese V, Cicero G, Vincenzi B, Tonini G, Santini D (2007). Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. *EXPERT OPINION ON THERAPEUTIC TARGETS*, vol. 11, p. 1571-1586, ISSN: 1472-8222, doi: 10.1517/14728222.11.12.1571
383. Santini D, Vincenzi B, Caraglia M, Tonini G (2007). A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. *ANNALS OF ONCOLOGY*, vol. 18, p. 201-U5, ISSN: 0923-7534, doi: 10.1093/annonc/mdl298
384. Santini D, Galluzzo S, Vincenzi B, Schiavon G, Fratto E, Pantano F, Tonini G (2007). New developments of aminobisphosphonates: the double face of Janus. *ANNALS OF ONCOLOGY*, vol. 18, p. 164-167, ISSN: 0923-7534, doi: 10.1093/annonc/mdm249
385. Schiavon G, Santini D, Vincenzi B, Tomm G (2007). European Society for Medical Oncology 2006: meeting highlights on targeted therapies - Istanbul, Turkey, 29 September-

- 3 October 2006. EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 7, p. 269-278, ISSN: 1471-2598, doi: 10.1517/14712598.7.2.269
386. Perrone G, Vincenzi B, Zagami M, Santini D, Panteri R, Flammia G, Verzi A, Lepanto D, Morini S, Russo A, Bazan V, Tomasino RM, Morello V, Tonini G, Rabitti C (2007). Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. MODERN PATHOLOGY, vol. 20, p. 344-351, ISSN: 0893-3952, doi: 10.1038/modpathol.3800743
387. Santini D, Virzi V, Vincenzi B, Rocci L, Leoni V, Tonini G (2007). A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. ANNALS OF ONCOLOGY, vol. 18, p. 576-580, ISSN: 0923-7534, doi: 10.1093/annonc/mdl440
388. Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, Dicuonzo G, Rocci L, Rosaria VM, Gebbia N, Tonini G (2007). Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. PHARMACOGENOMICS, vol. 8, p. 319-327, ISSN: 1462-2416, doi: 10.2217/14622416.8.4.319
389. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisogni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007). Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. JOURNAL OF CLINICAL ONCOLOGY, vol. 25, p. 1247-1254, ISSN: 0732-183X, doi: 10.1200/JCO.2006.08.1844
390. Santini D, Vincenzi B, Schiavon G, Di Seri M, Virzi V, Spalletta B, Caricato M, Coppola R, Tonini G (2007). Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 59, p. 613-620, ISSN: 0344-5704, doi: 10.1007/s00280-006-0302-x
391. Tonini G, Pantano F, Vincenzi B, Gabbriellini A, Coppola R, Santini D (2007). Molecular prognostic factors in patients with pancreatic cancer. EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 11, p. 1553-1569, ISSN: 1472-8222, doi: 10.1517/14728222.11.12.1553
392. SANTINI D, VINCENZI B, GALLUZZO S, BATTISTONI F, ROCCI L, VENDITTI O, SCHIAVON G, ANGELETTI S, UZZALLI F, CARAGLIA M, DICUONZO G, TONINI G (2007). Repeated intermittent low-dose therapy with zoledronic Acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. CLINICAL CANCER RESEARCH, vol. 13, p. 4482-4486, ISSN: 1078-0432
393. Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A (2007). R115777 (Zarnestra((R)))/Zoledronic acid (Zometa((R))) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. JOURNAL OF CELLULAR PHYSIOLOGY, vol. 211, p. 533-543, ISSN: 0021-9541, doi: 10.1002/jcp.20960
394. Tonini G, Schiavon G, Vincenzi B, Santini D (2007). New target agents in the treatment of colorectal cancer patients: the era after cetuximab and bevacizumab. EXPERT OPINION ON DRUG DISCOVERY, vol. 2, p. 861-871, ISSN: 1746-0441, doi: 10.1517/17460441.2.6.861
395. Perrone G, Zagami M, Santini D, Vincenzi B, Gullotta G, Morini S, Battista C, Guerriero G, Altomare V, Tonini G, Rabitti C (2007). COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification. HISTOPATHOLOGY, vol. 51, p. 33-39, ISSN: 0309-0167, doi: 10.1111/j.1365-2559.02731.x
396. Galluzzo S, Santini D, Vincenzi B, Caccamo N, Meraviglia S, Salerno A, Dieli F, Tonini G (2007). Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. EXPERT OPINION ON

- THERAPEUTIC TARGETS, vol. 11, p. 941-954, ISSN: 1472-8222, doi: 10.1517/14728222.11.7.941
397. Russo A, Gregorio V, Sisto PS, Calò V, Agnese V, Augello C, Cascio S, Badalamenti G, Fricano S, Napoli L, Giordano A, Santini D, Gebbia N, Bazan V (2006). Ductal lavage: a way of carefully tracing the breast-secreting duct. *THERAPY*, vol. 3, p. 389-393, ISSN: 1475-0708
  398. M CARAGLIA, SANTINI D, M MARRA, B VINCENZI, G TONINI, A BUDILLON (2006). Emerging anti-cancer molecular mechanisms of aminobisphosphonates. *ENDOCRINE-RELATED CANCER*, vol. 13, p. 7-26, ISSN: 1351-0088 319 2006
  399. Santini D, Schiavon G, Angeletti S, Vincenzi B, Gasparro S, Grilli C, La Cesa A, Virzi V, Leoni V, Budillon A, Addeo SR, Caraglia M, Dicuonzo G, Tonini G (2006). Last generation of amino-bisphosphonates (N-BPs) and cancer angiogenesis: A new role for these drugs?. *RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY*, vol. 1, p. 383-396, ISSN: 1574-8928, doi: 10.2174/157489206778776989
  400. Botev B, Casale M, Vincenzi B, D'Ascanio L, Santini D, Esposito V, Di Marino MP, Baldi A, Rinaldi V, Tonini G, Salvinelli F (2006). A giant sarcoma of the parotid gland: A case report and review of the literature. *IN VIVO*, vol. 20, p. 907-910, ISSN: 0258-851X
  401. Gentilucci UV, Santini D, Vincenzi B, Fiori E, Picardi A, Tonini G (2006). Chemotherapy-induced steatohepatitis in colorectal cancer patients. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 24, p. 5467, ISSN: 0732-183X, doi: 10.1200/JCO.2006.08.1828
  402. GRAZIANO F, KAWAKAMI K, WATANABE G, SANTINI D, CATALANO V, BISONNI R, CANESTRARI E, FICARELLI R, MENICHETTI ET, MARI D, TESTA E, SILVA R, CASCINU S, GIUSTINI L, TONINI G, AND MAGNANI M (2006). Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 24, p. 1883-1891, ISSN: 0732-183X
  403. Santini D, Fratto ME, Vincenzi B, Galluzzo S, Tonini G (2006). Zoledronic acid in the management of metastatic bone disease. *EXPERT OPINION ON BIOLOGICAL THERAPY*, vol. 6, p. 1333-1348, ISSN: 1471-2598, doi: 10.1517/14712598.6.12.1333
  404. Vincenzi B, Santini D, Holen I, Tonini G (2006). Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. *HAEMATOLOGICA REPORTS*, vol. 2, p. 50-51, ISSN: 1824-9337
  405. Santini D, Vincenzi B, Tonini G (2006). Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer? . *WOMEN'S HEALTH*, vol. 2, p. 1-3, ISSN: 1745-5057
  406. Vincenzi B, Santini D, Tonini G (2006). Taxanes in adjuvant chemotherapy for early breast cancer. *WOMEN'S HEALTH*, vol. 2, p. 323-325, ISSN: 1745-5057 327 2006
  407. Tonini G, Vincenzi B, Santini D (2006). Paraneoplastic syndromes: what we know and what we should know. *LA CLINICA TERAPEUTICA*, vol. 157, ISSN: 0009-9074
  408. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G (2006). The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. *EXPERT OPINION ON EMERGING DRUGS*, vol. 11, p. 665-683, ISSN: 1472-8214
  409. Vincenzi B, Santini D, Russo A, Dicuonzo G, Gavasci M, Battistoni F, Rocci L, Gebbia N, Tonini G (2006). Angiogenesis modifications are predictive of response and outcome advanced colorectal cancer patients during therapy with cetuximab plus irinotecan. *ANNALS OF ONCOLOGY*, vol. 17, p. 258, ISSN: 0923-7534
  410. Massacesi C, La Cesa A, Marcucci F, Pilone A, Rocchi MBL, Zepponi L, Santini D, Tonini G, Burattini L (2006). Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. *ONCOLOGY*, vol. 70, p. 294-300, ISSN: 0030-2414, doi: 10.1159/000096250
  411. Magistrelli P, Coppola R, Tonini G, Vincenzi B, Santini D, Borzomati D, Vecchio F, Valeri S, Castri F, Antinori A, Nuzzo G, Caraglia M, Picciocchi A (2006). Apoptotic index or

- a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. *JOURNAL OF CELLULAR BIOCHEMISTRY*, vol. 97, p. 98-108, ISSN: 0730-2312, doi: 10.1002/jcb.20621
412. Santini D, Altomare A, Vincenzi B, Perrone G, Bianchi A, Rabitti C, Montesarchio V, Esposito V, Baldi A, Tonini G (2006). Increase of CA 19.9 as the first clinical sign of ileocecal valve metastasis from breast cancer. *IN VIVO*, vol. 20, p. 165-168, ISSN: 0258-851X
413. Russo A, Terrasi M, Agnese V, Santini D, Bazan V (2006). Apoptosis: a relevant tool for anticancer therapy. *ANNALS OF ONCOLOGY*, vol. 17, p. VII115-VII123, ISSN: 0923-7534, doi: 10.1093/annonc/mdl963
414. Santini D, Vincenzi B, Schiavon G, La Cesa A, Gasparro S, Vincenzi A, Tonini G (2006). Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. *BMC CANCER*, vol. 6, ISSN: 1471-2407, doi: 10.1186/1471-2407-6-42
415. Santini D, Vincenzi B, Rosolowski M, Altucci L, Campioni M, Loeffler M, Baldi A, Tonini G (2006). Use of cDNA microarrays to estimate gene modulation profiles induced by zoledronic acid treatment in androgen-resistant prostate cancer cell line (PC3) . *HAEMATOLOGICA REPORTS*, ISSN: 1824-9337
416. Vincenzi B, Santini D, Tonini G (2006). Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan. *ANNALS OF ONCOLOGY*, vol. 17, ISSN: 0923-7534, doi: 10.1093/annonc/mdj014
417. Giorgio CG, Pappalardo A, Russo A, Giuffrida D, Santini D, Petralia G, Castorina S, Nunzio R, Failla G, Bordonaro R (2006). A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). *LUNG CANCER*, vol. 51, p. 357-362, ISSN: 0169-5002, doi: 10.1016/j.lungcan.2005.10.023
418. Graziano F, Kawakami K, Ruzzo A, Watanabe G, Santini D, Pizzagalli F, Bissoni R, Mari D, Floriani I, Catalano V, Silva R, Tonini G, Torri V, Giustini L, Magnani M (2006). Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. *INTERNATIONAL JOURNAL OF CANCER*, vol. 118, p. 628-632, ISSN: 0020-7136, doi: 10.1002/ijc.21397
419. Vincenzi B, Santini D, Tonini G (2006). Renal-cell carcinoma. *NEW ENGLAND JOURNAL OF MEDICINE*, vol. 354, p. 1095, ISSN: 0028-4793
420. Vincenzi B, Santini D, Rabitti C, Coppola R, Zobel BB, Trodella L, Tonini G (2006). Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. *BRITISH JOURNAL OF CANCER*, vol. 94, p. 792-797, ISSN: 0007-0920, doi: 10.1038/sj.bjc.6603018 341 2006
421. Vincenzi B, Santini D, Tonini G (2006). New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: The role of vascular endothelial growth factor. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 24, p. 1957, ISSN: 0732-183X, doi: 10.1200/JCO.2005.05.0450
422. Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M, Holen I (2006). Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. *ONCOLOGY REPORTS*, vol. 15, p. 1351-1357, ISSN: 1021-335X
423. Perrone G, Santini D, Verzi A, Vincenzi B, Borzomati D, Vecchio F, Coppola R, Antinori A, Magistrelli P, Tonini G, Rabitti C (2006). COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables. *JOURNAL OF CLINICAL PATHOLOGY*, vol. 59, p. 492-496, ISSN: 0021-9746, doi: 10.1136/jcp.2005.030098

424. Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N, Tonini G (2006). Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. *ANNALS OF ONCOLOGY*, vol. 17, p. 835-841, ISSN: 0923-7534, doi: 10.1093/annonc/mdl031
425. Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B, Vincenzi B, Russo A, Caraglia M, Virzi V, Cascinu S, Tonini G (2006). Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. *BMC CANCER*, vol. 6, ISSN: 1471-2407, doi: 10.1186/1471-2407-6-125
426. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G (2006). Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. *NATURE CLINICAL PRACTICE ONCOLOGY*, vol. 3, p. 325-338, ISSN: 1743-4254, doi: 10.1038/ncponc0520
427. Vincenzi B, Schiavon G, Silletta M, Santini D, Perrone G, Di Marino M, Angeletti S, Baldi A, Tonini G (2006). Cell cycle alterations and lung cancer. *HISTOLOGY AND HISTOPATHOLOGY*, vol. 21, p. 423-435, ISSN: 0213-3911
428. Abbate A, Limana F, Capogrossi MC, Santini D, Biondi-Zoccai GGL, Scarpa S, Germani A, Straino S, Severino A, Vasaturo F, Campioni M, Liuzzo G, Crea F, Vetrovec GW, Biasucci LM, Baldi A (2006). Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction. *APOPTOSIS*, vol. 11, p. 1061-1063, ISSN: 1360-8185, doi: 10.1007/s10495-006-6306-5
429. Abbate A, Scarpa S, Santini D, Palleiro J, Vasaturo F, Miller J, Morales C, Vetrovec GW, Baldi A (2006). Myocardial expression of survivin, an apoptosis inhibitor, in aging and heart failure. An experimental study in the spontaneously hypertensive rat. *INTERNATIONAL JOURNAL OF CARDIOLOGY*, vol. 111, p. 371-376, ISSN: 0167-5273, doi: 10.1016/j.ijcard.2005.07.061
430. Perrone G, Santini D, Zagami M, Vincenzi B, Verzi A, Morini S, Borzomati D, Coppola R, Antinori A, Magistrelli P, Tonini G, Rabitti C (2006). COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters. *VIRCHOWS ARCHIV*, vol. 449, p. 334-340, ISSN: 0945-6317, doi: 10.1007/s00428-006-0255-9
431. Zardi EM, Santini D, Vincenzi B, Galati G, Tonini G, Zobel BB, Afeltra A (2006). Surgical complications after resection of adrenal carcinoma. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 25, p. 449-451, ISSN: 0392-9078
432. Campioni M, Santini D, Tonini G, Murace R, Dragonetti E, Spugnini EP, Baldi A (2005). Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. *EXPERIMENTAL DERMATOLOGY*, vol. 14, p. 811-818, ISSN: 0906-6705, doi: 10.1111/j.1600-0625.2005.00360.x
433. Tonini G, Vincenzi B, Santini D (2005). New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. *EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY*, vol. 1, p. 143-149, ISSN: 1742-5255
434. Parisi Q, Biondi-Zoccai GG, Abbate A, Santini D, Vasaturo F, Scarpa S, Bussani R, Leone AM, Petrolini A, Silvestri F, Biasucci LM, Baldi A (2005). Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. *INTERNATIONAL JOURNAL OF CARDIOLOGY*, vol. 99, p. 337-339, ISSN: 0167-5273
435. Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, Baldi F, Rossiello L, Dell'Anna ML, Mastrofrancesco A, Maresca V, Flori E, Natali PG, Picardo M, Paggi MG (2005). Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. *CLINICAL CANCER RESEARCH*, vol. 11, p. 3175-3183, ISSN: 1078-0432
436. Esposito V, Baldi A, De Luca A, Tonini G, Vincenzi B, Santini D, Persichetti P, Mancini A, Citro G, Baldi F, Groeger AM, Caputi M. (2005). Cell cycle related proteins as

- prognostic parameters in radically resected non-small cell lung cancer. *JOURNAL OF CLINICAL PATHOLOGY*, vol. 58, p. 734-739, ISSN: 0021-9746
437. Abbate A, Bussani R, Biondi-Zoccai GG, Santini D, Petrolini A, De Giorgio F, Vasaturo F, Scarpa S, Severino A, Liuzzo G, Leone AM, Baldi F, Sinagra G, Silvestri F, Vetrovec GW, Crea F, Biasucci LM, Baldi A (2005). Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. *EUROPEAN HEART JOURNAL*, vol. 26, p. 2039-2045, ISSN: 0195-668X
438. Santini D, Vincenzi B, La Cesa A, Caricato M, Schiavon G, Spalletta B, Di Seri M, Coppola R, Rocci L, Tonini G (2005). Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. *ONCOLOGY*, vol. 69, p. 27-34, ISSN: 0030-2414, doi: 10.1159/000087285
439. Santini D, Vincenzi B, La Cesa A, Virzi V, Navajas F, Malafarina V, Dicuonzo G, Cassandro R, Esposito V, Montesarchio V, Groeger AM, Tonini G (2005). A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: An open-label, non randomized, pilot study. *ANTICANCER RESEARCH*, vol. 25, p. 669-674, ISSN: 0250-7005
440. Santini D, Tonini G, Vecchio FM, Borzomati D, Vincenzi B, Valeri S, Antinori A, Castri F, Coppola R, Magistrelli P, Nuzzo G, Picciocchi A (2005). Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. *JOURNAL OF CLINICAL PATHOLOGY*, vol. 58, p. 159-165, ISSN: 0021-9746, doi: 10.1136/jcp.2004.018887
441. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, Grilli C, Virzi V, Gasparro S, Rocci L, Tonini G (2005). Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. *JOURNAL OF INTERFERON AND CYTOKINE RESEARCH*, vol. 25, p. 144-151, ISSN: 1079-9907, doi: 10.1089/jir.2005.25.144
442. Vincenzi B, Santini D, Tonini G (2005). Thymidylate synthase expression in colorectal cancer: The never-ending story. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 23, p. 2108, ISSN: 0732-183X, doi: 10.1200/JCO.2005.05.178
443. Graziano F, Ruzzo A, Santini D, Humar B, Tonini G, Catalano V, Berardi R, Pizzagalli F, Arduini F, Bearzi I, Scartozzi M, Cascinu S, Testa E, Ficarelli R, Magnani M (2005). Prognostic role of interleukin-1 beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 23, p. 2339-2345, ISSN: 0732-183X, doi: 10.1200/JCO.2005.02.345
444. Tonini G, Vincenzi B, Santini D, Olzi D, Lambiase A, Bonini S (2005). Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*, vol. 97, p. 606-607, ISSN: 0027-8874, doi: 10.1093/jnci/dji104
445. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C (2005). COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. *HISTOPATHOLOGY*, vol. 46, p. 561-568, ISSN: 0309-0167, doi: 10.1111/j.1365-2559.2005.02132.x
446. Santini D, Vincenzi B, Tonini G, Scarpa S, Vasaturo F, Malacrino C, Vecchio F, Borzomati D, Valeri S, Coppola R, Magistrelli P, Nuzzo G, Picciocchi A (2005). Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients. *CLINICAL CANCER RESEARCH*, vol. 11, p. 3784-3789, ISSN: 1078-0432, doi: 10.1158/1078-0432.CCR-04-2136
447. Ruzzo A, Graziano F, Pizzagalli F, Santini D, Battistelli V, Panunzi S, Canestrari E, Catalano V, Humar B, Ficarelli R, Bearzi I, Cascinu S, Naldi N, Testa E, Magnani M (2005). Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse

- histotype. ANNALS OF ONCOLOGY, vol. 16, p. 887-892, ISSN: 0923-7534, doi: 10.1093/annonc/mdi184
448. Tonini G, Vincenzi B, Santini D, Scarpa S, Vasaturo T, Malacrino C, Coppola R, Magistrelli P, Borzomati D, Baldi A, Antinori A, Caricato M, Nuzzo G, Picciocchi A (2005). Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. BRITISH JOURNAL OF CANCER, vol. 92, p. 2225-2232, ISSN: 0007-0920, doi: 10.1038/sj.bjc.6602632
449. Giorgio CG, Giuffrida D, Pappalardo A, Russo A, Santini D, Salice P, Blanco G, Castorina S, Failla G, Bordonaro R (2005). Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: Phase II study. LUNG CANCER, vol. 50, p. 247-254, ISSN: 0169-5002, doi: 10.1016/j.lungcan.2005.05.026
450. Cristi E, Perrone G, Toscano G, Verzi A, Nori S, Santini D, Tonini G, Vetrani A, Fabiano A, Rabitti C (2005). Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. JOURNAL OF CLINICAL PATHOLOGY, vol. 58, p. 1170-1174, ISSN: 0021-9746, doi: 10.1136/jcp.2004.025536
451. Santini D, Vincenzi B, Perrone G, Rabitti C, Borzomati D, Valeri S, Coppola R, Magistrelli P, Tonini G (2005). Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma. ANNALS OF ONCOLOGY, vol. 16, p. 1847-U4, ISSN: 0923-7534, doi: 10.1093/annonc/mdi353
452. Kawakami K, Graziano F, Watanabe G, Ruzzo A, Santini D, Catalano V, Bissoni R, Arduini F, Bearzi I, Cascinu S, Mureto P, Perrone G, Rabitti C, Giustini L, Tonini G, Pizzagalli F, Magnani M. (2005). Prognostic role of Thymidylate Synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy . CLINICAL CANCER RESEARCH, ISSN: 1078-0432
453. Graziano F, Kawakami K, Watanabe G, Ruzzo A, Humar B, Santini D, Catalano V, Ficarelli R, Merriman T, Panunzi S, Testa E, Cascinu S, Bearzi I, Tonini G, Magnani M (2004). Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. INTERNATIONAL JOURNAL OF CANCER, vol. 112, p. 1010-1014, ISSN: 0020-7136, doi: 10.1002/ijc.20489
454. Santini D, Abbate A, Scarpa S, Vasaturo F, Biondi-Zoccai GG, Bussani R, De Giorgio F, Bassan F, Camilot D, Di Marino MP, Feroce F, Baldi F, Silvestri F, Crea F (2004). Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction. JOURNAL OF CLINICAL PATHOLOGY, vol. 57, p. 1321-1324, ISSN: 0021-9746, doi: 10.1136/jcp.2004.018986
455. Vincenzi B, Santini D, Grilli C, La Cesa A, Dianzani C, Tonini G (2004). Case 3. Toxic epidermal necrolysis induced by oral phenobarbital and whole-brain radiotherapy in a breast cancer patient. JOURNAL OF CLINICAL ONCOLOGY, vol. 22, p. 4649-4651, ISSN: 0732-183X, doi: 10.1200/JCO.2004.05.003
456. Vincenzi B, La Cesa A, Santini D, Schiavon G, Grilli C, Graziano F, Tonini G (2004). Predictive factors for response to chemotherapy in colorectal cancer patients. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 52, p. 45-60, ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2004.05.005
457. Perrone G, Vincenzi B, Santini D, Verzi A, Tonini G, Vetrani A, Rabitti C (2004). Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinicopathological features in colon cancer. CANCER LETTERS, vol. 208, p. 227-234, ISSN: 0304-3835, doi: 10.1016/j.canlet.2003.11.032
458. Roila F, Ballatori E, Bosnjak S, Tonato M, Basurto C, Betti M, Bonciarelli V, Cianchetti M, Susnjar S, Neskovic-Konstantinovic Z, Stamatovic L, Marinkovic Z, Rosati G, Manzione L, Rossi A, Germano D, Romano R, Nuzzo A, Laudadio L, D'Ostilio N, Forciniti S, Buzzi F, Bartolucci R, Fumi G, Catanzani S, Gamucci T, Ferraresi V, Trombetta G, Vaccaro A, Contu A, Olmeo N, Baldino G, Campora E, Venturino A, Addamo G, Silva RR, Giuliadori L, Bissoni R, Dazzi C, Cariello A, Zumaglini F, Tonini G, Santini D, Vincenzi B, Fava S, Grimi E, Luoni M, Picece V, Nicodemo M, Recaldin E, Donati D, Margutti G,

- Cortesi E, D'Auria G, Lalli A, Di Giandomenico F, Massidda B, Ionta MT, Alessandrini P, Baldelli AM, Pinaglia D, Sassi M, Sabbatini R, Maur M, di Castello C, Porrozzi S, Bravi S, Eugenio S, Antimi M, Gridelli C, Verusio C (2004). Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide (vol 22, pg 725, 2004). *JOURNAL OF CLINICAL ONCOLOGY*, vol. 22, p. 2038, ISSN: 0732-183X, doi: 10.1200/JCO.2004.03.955
459. Vincenzi B, Santini D, La Cesa A, Tonini G (2004). Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. *CANCER*, vol. 100, p. 1987-1988, ISSN: 0008-543X, doi: 10.1002/cncr.20194
460. Baldi A, Santini D, Vasaturo F, Santini M, Vicidomini G, Di Marino MP, Esposito V, Groeger AM, Liuzzi G, Vincenzi B, Tonini G, Piccoli M, Baldi F, Scarpa S (2004). Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. *THORAX*, vol. 59, p. 428-433, ISSN: 0040-6376, doi: 10.1136/thx.2003.008912
461. Abbate A, Santini D, Biondi-Zoccai GGL, Scarpa S, Vasaturo F, Liuzzo G, Bussani R, Silvestri F, Baldi F, Crea F, Biasucci LM, Baldi A (2004). Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?. *HEART*, vol. 90, p. 440-443, ISSN: 1355-6037, doi: 10.1136/hrt.2003.010280
462. Biondi-Zoccai GGL, Abbate A, Vasaturo F, Scarpa S, Santini D, Leone AM, Parisi Q, De Giorgio F, Bussani R, Silvestri F, Baldi F, Biasucci LM, Baldi A (2004). Increased apoptosis in remote non-infarcted myocardium in multivessel coronary disease. *INTERNATIONAL JOURNAL OF CARDIOLOGY*, vol. 94, p. 105-110, ISSN: 0167-5273, doi: 10.1016/j.ijcard.2003.07.001
463. Leoni V, Santini D, Vincenzi B, Grilli C, Onori N, Tonini G (2004). Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions. *ALLERGY*, vol. 59, p. 241, ISSN: 0105-4538, doi: 10.1046/j.1398-9995.2003.00383.x
464. Baldi A, Santini D, Russo P, Catricala C, Amantea A, Picardo M, Tatangelo F, Botti G, Dragonetti E, Murace R, Tonini G, Natali PG, Baldi F, Paggi MG (2004). Analysis of APAF-1 expression in human cutaneous melanoma progression. *EXPERIMENTAL DERMATOLOGY*, vol. 13, p. 93-97, ISSN: 0906-6705, doi: 10.1111/j.0906-6705.2004.00136.x
465. Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G (2004). Bisphosphonate effects in cancer and inflammatory diseases - In vitro and in vivo modulation of cytokine activities. *BIODRUGS*, vol. 18, p. 269-278, ISSN: 1173-8804, doi: 10.2165/00063030-200418040-00004
466. Schiavon G, Vincenzi B, Santini D, Avvisati G, Tonini G (2004). Recurrent thrombophlebitis in a colon cancer patient with C677T heterozygous genotype for MTHFR treated with 5-fluorouracil-based adjuvant chemotherapy. *CHEMOTHERAPY*, vol. 50, p. 194-195, ISSN: 0009-3157, doi: 10.1159/000081031
467. Santini D, Massacesi C, D'Angelillo RM, Marcucci T, Campisi C, Vincenzi B, Piloni A, Bianco V, Bonsignori M, Tonini G (2004). Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer – A multicenter non-randomized phase II study. *MEDICAL ONCOLOGY*, vol. 21, p. 59-66, ISSN: 1357-0560, doi: 10.1385/MO:21:1:59
468. Santini D, Vincenzi B, Perrone G, Rabitti C, Borzomati D, Caricato M, La Cesa A, Grilli C, Verzi A, Coppola R, Tonini G (2004). Thymidylate synthase expression in normal colonic mucosa: A predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. *ONCOLOGY*, vol. 67, p. 135-142, ISSN: 0030-2414, doi: 10.1159/000081000
469. Landi D, Santini D, Vincenzi B, La Cesa A, Dianzani C, Tonini G (2003). Dramatic improvement of psoriasis with gemcitabine monotherapy. *BRITISH JOURNAL OF DERMATOLOGY*, vol. 149, p. 1306-1307, ISSN: 0007-0963, doi: 10.1111/j.1365-2133.2003.05667.x



470. Santini D, Vincenzi B, Massacesi C, Picardi A, Gentilucci UV, Esposito V, Liuzzi G, La Cesa A, Rocci L, Marcucci F, Montesarchio V, Groeger AM, Bonsignori M, Tonini G, Baldi A (2003). S-Adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. *ANTICANCER RESEARCH*, vol. 23, p. 5173-5179, ISSN: 0250-7005
471. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G (2003). Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. *JOURNAL OF INTERFERON AND CYTOKINE RESEARCH*, vol. 23, p. 649-654, ISSN: 1079-9907, doi: 10.1089/107999003322558782
472. Santini D, Vincenzi B, La Cesa A, Casale M, Sal Vinelli F, Tonini G (2003). Recurrent episodes of involuntary masticatory spasms induced by continuous infusion of oxaliplatin. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*, vol. 95, p. 1555-1556, ISSN: 0027-8874, doi: 10.1093/jnci/djg087
473. Santini D, Gentilucci UV, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S, Tonini G (2003). The antineoplastic role of bisphosphonates: from basic research to clinical evidence. *ANNALS OF ONCOLOGY*, vol. 14, p. 1468-1476, ISSN: 0923-7534, doi: 10.1093/annonc/mdg401
474. De Luca A, De Falco M, Severino A, Campioni M, Santini D, Baldi F, Paggi MG, Baldi A (2003). Distribution of the serine protease HtrA1 in normal human tissues. *JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY*, vol. 51, p. 1279-1284, ISSN: 0022-1554
475. Vincenzi B, Santini D, Avvisati G, Borzomati D, Tonini G (2003). Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. *BRITISH JOURNAL OF SURGERY*, vol. 90, p. 1165-1166, ISSN: 0007-1323, doi: 10.1002/bjs.4378
476. Vincenzi B, Santini D, La Cesa A, Tonini G (2003). Cancer chronotherapy: Principles, applications, and perspectives. *CANCER*, vol. 98, p. 881-882, ISSN: 0008-543X, doi: 10.1002/cncr.11600
477. Massacesi C, Santini D, Rocchi MBL, La Cesa A, Marcucci F, Vincenzi B, Delprete S, Tonini G, Bonsignori M (2003). Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. *ANTI-CANCER DRUGS*, vol. 14, p. 533-541, ISSN: 0959-4973, doi: 10.1097/01.cad.0000086655.37889.f8
478. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G (2003). Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. *CLINICAL CANCER RESEARCH*, vol. 9, p. 2893-2897, ISSN: 1078-0432
479. Santini D, Vincenzi B, Tonini G (2003). Letter to the editor. *CLINICAL CANCER RESEARCH*, vol. 9, p. 3215, ISSN: 1078-0432
480. Vincenzi B, Santini D, Avvisati G, Baldi A, La Cesa A, Tonini G (2003). Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?. *MEDICAL HYPOTHESES*, vol. 61, p. 98-101, ISSN: 0306-9877, doi: 10.1016/S0306-9877(03)00124-5
481. Tonini G, Vincenzi B, Santini D, Avvisati G, La Cesa A, Baldi A (2003). Unusual problems in breast cancer and a rare lung cancer case - Case 1. Clinical complete response of breast cancer metastases after trastuzumab-based immunotherapy. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 21, p. 2215-2216, ISSN: 0732-183X, doi: 10.1200/JCO.2003.04.195
482. Tonini G, Vincenzi B, Di Cosimo S, Gravante G, Santini D, Ambrogi V, Micheletti E, Rocci L, D'Aprile M (2003). Fatal thrombocytopenia and thrombocytopathia: An unusual onset of non small cell lung cancer. *ONKOLOGIE*, vol. 26, p. 272-274, ISSN: 0378-584X, doi: 10.1159/000071624
483. Vincenzi B, Santini D, Rocci L, Tonini G (2003). Bisphosphonates: new antiangiogenic molecules in cancer treatment?. *ANNALS OF ONCOLOGY*, vol. 14, p. 806-807, ISSN: 0923-7534, doi: 10.1093/annonc/mdg194

484. Tonini G, Vincenzi B, Santini D, La Cesa A, Finolezzi E, Onori N, D'Angelillo R, Baldi A, Trodella L (2003). Prevention of radiotherapy-induced emesis. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 22, p. 17-22, ISSN: 0392-9078
485. Salvinelli F, Casale M, Vincenzi B, Santini D, Di Peco V, Firrisi L, Onori N, Greco F, Tonini G (2003). Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 22, p. 155-158, ISSN: 0392-9078
486. Santini D, Picardi A, Vincenzi B, Binetti P, Massacesi C, La Cesa A, Tonini G (2003). Severe liver dysfunction after raltitrexed administration in an HCV-positive colorectal cancer patient. *CANCER INVESTIGATION*, vol. 21, p. 162-163, ISSN: 0735-7907, doi: 10.1081/CNV-120016411
487. Baldi A, Battista T, De Luca A, Santini D, Rossiello L, Baldi F, Natali PG, Lombardi D, Picardo M, Felsani A, Paggi MG (2003). Identification of genes down-regulated during melanoma progression: a cDNA array study. *EXPERIMENTAL DERMATOLOGY*, vol. 2, p. 213-218, ISSN: 0906-6705
488. Baldi A, Santini D, De Luca A, Paggi MG (2003). cDNA array technology in melanoma: an overview. *JOURNAL OF CELLULAR PHYSIOLOGY*, vol. 196, p. 219-223, ISSN: 0021-9541
489. Graziano F, Santini D, Testa E, Catalano V, Beretta GD, Mosconi S, Tonini G, Lai V, Labianca R, Cascinu S (2003). A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. *BRITISH JOURNAL OF CANCER*, vol. 89, p. 1428-1432, ISSN: 0007-0920
490. Santini D, Vincenzi B, Tonini G, Scarpa S, Baldi A (2003). Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. *CLINICAL CANCER RESEARCH*, vol. 9, ISSN: 1078-0432
491. Bianco V, Rozzi A, Tonini G, Santini D, Magnolfi E, Vincenzi B, D'Angelillo R, Marchei P (2002). Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): A phase II study. *ANTICANCER RESEARCH*, vol. 22, p. 3053-3056, ISSN: 0250-7005
492. Baldi A, Santini D, Vicidomini G, Ambrosino F, Vincenzi B, Costanzo R, Di Leo C, Esposito V, Groeger AM, Baldi F (2002). Papillary pneumocytoma of the lung simulating a pleomorphic adenoma. *IN VIVO*, vol. 16, p. 387-390, ISSN: 0258-851X
493. Vincenzi B, Santini D, Spoto S, Finolezzi E, D'Angelillo RM, La Cesa A, Tonini G (2002). The antineoplastic treatment in the elderly. *LA CLINICA TERAPEUTICA*, vol. 153, p. 207-215, ISSN: 0009-9074
494. Esposito V, Groeger AM, De Luca L, Di Marino M, Santini D, Marchei P, Baldi F, Wolner E, Baldi A (2002). Expression of surface protein receptors in lung cancer. *ANTICANCER RESEARCH*, vol. 22, p. 4039-4043, ISSN: 0250-7005
495. Santini D, Tonini G, Vincenzi B, Murace R, Ferranti G, Baldi A (2002). Skin lesions in melanoma and Kaposi's sarcoma - Case 1. Detection of circulating malignant cells by RT-PCR in a case of cutaneous melanoma in complete regression. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 20, p. 1411-1412, ISSN: 0732-183X
496. Tonini G, Santini D, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A, Onori N, Coppola R (2002). Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. *JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS*, vol. 16, p. 105-109, ISSN: 0393-974X
497. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G (2002). Pamidronate induces modifications of circulating angiogenic factors in cancer patients. *CLINICAL CANCER RESEARCH*, vol. 8, p. 1080-1084, ISSN: 1078-0432
498. Cascinu S, Graziano F, Ferrau F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R (2002). Raltitrexed plus

- oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). *ANNALS OF ONCOLOGY*, vol. 13, p. 716-720, ISSN: 0923-7534, doi: 10.1093/annonc/mdf091
499. Tonini G, Santini D, Vincenzi B, Dicuonzo G, Salerno A, Finolezzi E, Avvisati G (2002). Raltitrexed as monochemotherapy induces a statistically significant increase in platelet count. *ACTA ONCOLOGICA*, vol. 41, p. 315-316, ISSN: 0284-186X
  500. Gentilucci UV, Santini D, Picardi A, Vincenzi B, Riva E, Bianchi A, Tonini G (2002). Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor. *JOURNAL OF INTERFERON AND CYTOKINE RESEARCH*, vol. 22, p. 683-688, ISSN: 1079-9907, doi: 10.1089/10799900260100178
  501. Romiti A, Tonini G, Santini D, Di Seri M, Masciangelo R, Mezi S, Veri A, Santuari L, Vincenzi B, Brescia A, Marchei P, Frati L, Tomao S (2002). Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer. *ANTICANCER RESEARCH*, vol. 22, p. 3071-3076, ISSN: 0250-7005
  502. Dicuonzo G, Angeletti S, Garcia-Foncillas J, Brugarolas A, Okrouzhnov Y, Santini D, Tonini G, Lorino G, De Cesaris M, Baldi A (2001). Colorectal carcinomas and PTEN/MMAC1 gene mutations. *CLINICAL CANCER RESEARCH*, vol. 7, p. 4049-4053, ISSN: 1078-0432
  503. Baldi A, Santini D, Paggi MG (2001). Association for Molecular Pathology: Sixth annual meeting in Denver, November 9-12, 2000. *JOURNAL OF CELLULAR PHYSIOLOGY*, vol. 188, p. 139-142, ISSN: 0021-9541
  504. Baldi A, Santini D, Battista T, Dragonetti E, Ferranti G, Petitti T, Groeger AM, Angelini A, Rossiello R, Baldi F, Natali PG, Paggi MG (2001). Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. *JOURNAL OF CELLULAR BIOCHEMISTRY*, vol. 83, p. 364-372, ISSN: 0730-2312
  505. Santini D, Vincenzi B, Fossati C, D'Angelillo RM, Patti G, Bianco V, Avvisati G, Tonini G (2001). Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis - A pilot study with ACTH-Depot plus tropisetron. *MEDICAL ONCOLOGY*, vol. 18, p. 131-135, ISSN: 1357-0560
  506. Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Battistoni F, Dicuonzo G, Labianca R (2001). Idiosyncratic reaction after oxaliplatin infusion. *ANNALS OF ONCOLOGY*, vol. 12, p. 132-133, ISSN: 0923-7534, doi: 10.1023/A:1008366223918
  507. Vincenzi B, Finolezzi E, Fossati C, Verzi A, Santini D, Tonini G, Arullani A, Avvisati G (2001). Unusual presentation of Hodgkin's disease mimicking inflammatory bowel disease. *LEUKEMIA & LYMPHOMA*, vol. 42, p. 521-526, ISSN: 1042-8194, doi: 10.3109/10428190109064611 428 2000
  508. Dieli F, Singh M, Spallek R, Romano A, Titone L, Sireci G, Friscia G, Di Sano C, Santini D, Salerno A, Ivanyi J (2000). Change of Th0 to Th1 cell-cytokine profile following tuberculosis chemotherapy. *SCANDINAVIAN JOURNAL OF IMMUNOLOGY*, vol. 52, p. 96-102, ISSN: 0300-9475
  509. Santini D, Tonini G, Abbate A, Di Cosimo S, Gravante G, Vincenzi B, Campisi C, Patti G, Di Sciascio G (2000). Gemcitabine-induced atrial fibrillation: A hitherto unreported manifestation of drug toxicity. *ANNALS OF ONCOLOGY*, vol. 11, p. 479-481, ISSN: 0923-7534, doi: 10.1023/A:1008380208045
  510. Baldi A, Rossiello R, Di Marino M, Ferrara N, Groeger AM, Esposito V, Santini D, Kaiser HE, Baldi F (2000). Colonic type adenocarcinoma of male urethra. *IN VIVO*, vol. 14, p. 487-492, ISSN: 0258-851X
  511. Baldi A, Dragonetti E, Battista T, Groeger AM, Esposito V, Baldi G, Santini D (2000). Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients. *ANTICANCER RESEARCH*, vol. 20, p. 3923-3928, ISSN: 0250-7005

512. Groeger AM, Baldi A, Caputi M, Esposito V, Russo P, Severino A, Santini D, Rossiello R, Kaiser HE, Baldi F (2000). Intrapulmonary teratoma associated with thymic tissue. *ANTICANCER RESEARCH*, vol. 20, p. 3919-3922, ISSN: 0250-7005
513. Groeger AM, Caputi M, Esposito V, Baldi A, Rossiello R, Santini D, Mancini A, Kaiser HE, Baldi F (2000). Expression of p21 in non small cell lung cancer relationship with PCNA. *ANTICANCER RESEARCH*, vol. 20, p. 3301-3305, ISSN: 0250-7005
514. D'Aprile M, Santini D, Di Cosimo S, Gravante G, Vincenzi B, Spoto S, Costantino S, Rabitti C, Tonini G (2000). Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature review. *LA CLINICA TERAPEUTICA*, vol. 151, p. 371-374, ISSN: 0009-9074
515. Santini D, Binetti P (2000). [The tutorial dimension of clinical training of students]. . *LA CLINICA TERAPEUTICA*, vol. 151, p. 97-102, ISSN: 0009-9074 436 1999
516. Santini D, Vincenzi B, Finolezzi E, Di Cosimo S, Gravante G, Spoto S, Tonini G (1999). [The prevention of vomiting due to antineoplastic chemotherapy in the elderly cancer patient]. . *MINERVA MEDICA*, vol. 90, p. 205-209, ISSN: 0026-4806
517. Baldi A, Groeger AM, Esposito V, Di Lieto E, Di Marino MP, Santini D, Baldi F (1998). Lymphomatoid granulomatosis of the lung: a clinico-pathological study. *ANTICANCER RESEARCH*, vol. 18, p. 4621-4624, ISSN: 0250-7005
518. Marchei P, Lanza R, Poggi A, Santini D, Speranza I, Bianco V, Simeoni F (1997). A rare case of primary lymphoma of the breast and metachronous breast primitive lobular carcinoma: case report. *EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY*, vol. 18, p. 511-512, ISSN: 0392-2936
519. MARCHEI P, SIMEONI F, BIANCO V, SANTINI D, BALDUCCI M, VECCHIONE A, FRATI L. (1997). ASSISTENZA EXTRAOSPEDALIERA AL PAZIENTE ONCOLOGICO TERMINALE : ASPETTI CLINICO-ORGANIZZATIVI. NOSTRA ESPERIENZA = HOME CARE FOR TERMINAL CANCER PATIENTS : CLINICAL AND ORGANIZATIONAL ASPECTS. PERSONAL EXPERIENCE . *MINERVA MEDICA*, vol. 88, p. 25-30, ISSN: 0026-4806
520. Marchei P, Bianco V, Pignatelli E, Chiodini S, Santini D, Carico E, Marchei M, Vecchione A (1996). Adjuvant treatment for breast cancer in the elderly. *ANTICANCER RESEARCH*, vol. 16, p. 911-913, ISSN: 0250-7005
521. Marchei P, Santini D, Bianco V, Chiodini S, Reale MG, Simeoni F, Marchei GG, Vecchione A (1995). Serum ostase in the follow-up of breast cancer patients. *ANTICANCER RESEARCH*, vol. 15, p. 2217-2222, ISSN: 0250-7005
522. REALE MG, SANTINI D, CHIODINI S, IZZO P, MARCHEI P, FRATI L (1995). TUMOR-MARKERS IN COLORECTAL-CANCER. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 14, p. 19-27, ISSN: 0392-9078
523. Santini D, Simeoni F, Bianco V, Chiodini S, Speranza I, Pignatelli E, Marchei P (1995). [Treatment of stage-I seminoma. Critical review]. *MINERVA UROLOGICA E NEFROLOGICA*, vol. 47, p. 31-38, ISSN: 0393-2249
524. Reale MG, Santini D, Marchei GG, Manna A, Del Nero A, Bianco V, Marchei P, Frati L (1995). Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer. *THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS*, vol. 10, p. 42-46, ISSN: 0393-6155